1
|
Moore CM, Pan CX, Roseman K, Stephens MM, Bien-Aime C, Morgan AC, Ross W, Castillo MC, Palathra BC, Jones CA, Ailey S, Tuffrey-Wijne I, Smeltzer SC, Tobias J. Top Ten Tips Palliative Care Clinicians Should Know About Navigating the Needs of Adults with Intellectual Disabilities. J Palliat Med 2022; 25:1857-1864. [PMID: 36083260 DOI: 10.1089/jpm.2022.0384] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
Abstract
As many people with intellectual disabilities (ID) live longer, the need for access to quality palliative care (PC) rises. People with ID realize significant barriers and inequities in accessing health care and PC. The need for integrated disability and PC services with extensive collaboration is great. The following tips are for PC clinicians caring for people with ID, their families, caregivers, and the community. While patient-centered care is difficult to distill into "tips," this article, written by an interdisciplinary team of PC and ID specialists, offers resources and references to improve the care provided to people with ID and serious illnesses.
Collapse
Affiliation(s)
- Caitlyn M Moore
- Jefferson College of Nursing, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.,Inpatient Palliative Care and Hospice, Main Line Health, Radnor, Pennsylvania, USA
| | - Cynthia X Pan
- Division of Geriatrics and Palliative Care Medicine, New York-Presbyterian Queens Hospital, Flushing, New York, USA.,Department of Medicine, Weill Cornell Medical College, New York, New York, USA
| | - Karin Roseman
- Department of Family and Community Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.,Jefferson Continuing Care Program, Jefferson Health, Philadelphia, Pennsylvania, USA
| | - Mary M Stephens
- Department of Family and Community Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.,Jefferson Continuing Care Program, Jefferson Health, Philadelphia, Pennsylvania, USA
| | - Casey Bien-Aime
- Pastoral Care Department, Lankenau Medical Center, Wynnewood, Pennsylvania, USA
| | - Ann C Morgan
- New York State Office for People with Developmental Disabilities, Region 6, Queens, New York, USA
| | - Wendy Ross
- Jefferson Center for Autism and Neurodiversity, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA
| | - Matthew C Castillo
- Division of Geriatrics and Palliative Care Medicine, New York-Presbyterian Queens Hospital, Flushing, New York, USA
| | - Brigit C Palathra
- Division of Geriatrics and Palliative Care Medicine, New York-Presbyterian Queens Hospital, Flushing, New York, USA.,Department of Medicine, Weill Cornell Medical College, New York, New York, USA
| | - Christopher A Jones
- Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA
| | - Sarah Ailey
- Department of Community, Systems, and Mental Health Nursing, Rush University, College of Nursing, Chicago, Illinois, USA
| | - Irene Tuffrey-Wijne
- Center for Health and Social Care Research, Kingston University, University of London, London, United Kingdom
| | - Suzanne C Smeltzer
- M. Louise Fitzpatrick College of Nursing, Villanova University, Villanova, Pennsylvania, USA
| | - Jane Tobias
- Jefferson College of Nursing, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
| |
Collapse
|
2
|
Manning ML, Tobias J. Using Visual Explorer to Ignite Dialogue in a Doctoral Leadership Course. J Nurs Educ 2022; 61:59. [PMID: 35025676 DOI: 10.3928/01484834-20211201-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Affiliation(s)
| | - Jane Tobias
- Thomas Jefferson University, Jefferson College of Nursing
| |
Collapse
|
3
|
Tobias J, Garner-Spitzer E, Drinić M, Wiedermann U. Vaccination against Her-2/neu, with focus on peptide-based vaccines. ESMO Open 2022; 7:100361. [PMID: 35026721 PMCID: PMC8760406 DOI: 10.1016/j.esmoop.2021.100361] [Citation(s) in RCA: 17] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2021] [Revised: 11/29/2021] [Accepted: 11/29/2021] [Indexed: 12/11/2022] Open
Abstract
Immunotherapy has been a milestone in combatting cancer, by complementing or even replacing classic treatments like surgery, chemotherapy, radiation, and anti-hormonal therapy. In 15%-30% of breast cancers, overexpression of the human epidermal growth factor receptor 2 (Her-2/neu) is associated with more aggressive tumor development. Passive immunization/immunotherapy with the recombinantly produced Her-2/neu-targeting monoclonal antibodies (mAbs) pertuzumab and trastuzumab has been shown to effectively treat breast cancer and lead to a significantly better prognosis. However, allergic and hypersensitivity reactions, cardiotoxicity, development of resistance, lack of immunological memory which results in continuous application over a long period, and cost-intensiveness are among the drawbacks associated with this treatment. Furthermore, intrinsic or acquired resistance is associated with the application of therapeutic mAbs, leading to the disease recurrence. Conversely, these drawbacks could be potentially overcome by vaccination, i.e. an active immunization/immunotherapy approach by activating the patient’s own immune system to target cancer, along with inducing immunological memory. This review aims to summarize the main approaches investigated and undertaken for the production of Her-2/neu vaccine candidates, with the main focus on peptide-based vaccines and their evaluation in clinical settings. Her-2/neu is overexpressed in 10%-30% of breast and gastric cancer patients and this correlates with poor clinical outcomes. Passive application of trastuzumab and pertuzumab has outstandingly improved the Her-2/neu-related clinical outcomes. Treatment with mAbs is associated with frequent administration, cost-intensiveness, and resistance. Vaccination against Her-2/neu with e.g. mimotope- or peptide-based vaccines can alternatively overcome the mAbs’ drawbacks. Such alternatives may pave the way to therapeutics which could be used as monotherapy or in combination therapies with mAbs.
Collapse
Affiliation(s)
- J Tobias
- Institute of Specific Prophylaxis and Tropical Medicine, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.
| | - E Garner-Spitzer
- Institute of Specific Prophylaxis and Tropical Medicine, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
| | - M Drinić
- Institute of Specific Prophylaxis and Tropical Medicine, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
| | - U Wiedermann
- Institute of Specific Prophylaxis and Tropical Medicine, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.
| |
Collapse
|
4
|
Abstract
The preterm birth rate in the United States is 10%, with 8% being born between 36 and 32 weeks of gestation, and the remaining 2% born less than 31 weeks of gestation. The global preterm birth rate varies from 5% to 18%, with varying survival rates. These percentages signify a population of people that will receive health care across the life course without ever being asked about a preterm birth history. With a steady rise in the survival rate of preterm infants being discharged home from the neonatal intensive care unit, with limited referrals for neonatal or developmental follow up, it is essential adult care providers ask the right questions and identify risk factors for this vulnerable population. This review describes the recently published, evidence-based recommendations for addressing preterm history across the life course. A robust review of the literature has demonstrated that the long-term sequelae of being born preterm can adversely affect health and quality of life. The following will offer preterm birth history recommendations based on assessment and diagnosis, prevention and management and referral and treatment. The goal of the recommendations is to create awareness among adult health providers in acknowledging a past medical history of preterm birth and providing appropriate preventive care, therefore shifting the paradigm of care from reactive intervention to proactive care.
Collapse
Affiliation(s)
- Michelle M Kelly
- Villanova University, Fitzpatrick College of Nursing, United States of America; University of Rhode Island, College of Nursing, Research Fellow, United States of America.
| | - Jane Tobias
- Thomas Jefferson University, Jefferson College of Nursing, United States of America
| |
Collapse
|
5
|
Kelly MM, Tobias J, Griffith PB. Addressing Preterm Birth History With Clinical Practice Recommendations Across the Life Course. J Pediatr Health Care 2021; 35:e5-e20. [PMID: 33637388 DOI: 10.1016/j.pedhc.2020.12.008] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/12/2020] [Revised: 12/12/2020] [Accepted: 12/18/2020] [Indexed: 12/19/2022]
Abstract
Preterm birthrates, coupled with excellent preterm birth survival rates, guarantee that every health care provider, regardless of specialty, is caring for patients who were born preterm. Patients and families may not share a preterm birth history however, eliciting this information is important for mitigating potential risk. Long-term health outcomes research supports health implications associated with preterm birth throughout the life course. Through an in-depth review of literature and validation from health care experts in pediatric and adult care, recommendations for primary care providers were developed. The aim was to enhance the identification of those born prematurely, empower health care providers to employ familiar screening strategies, and advocate for mitigations strategies with anticipatory guidance and health promotion. These recommendations advocate a paradigm shift toward proactive intervention, rather than the reactive practice of waiting for children to fail to meet specific milestones or begin to show comorbid tendencies.
Collapse
|
6
|
Heydinger G, Tobias J, Veneziano G. Fundamentals and innovations in regional anaesthesia for infants and children. Anaesthesia 2021; 76 Suppl 1:74-88. [PMID: 33426659 DOI: 10.1111/anae.15283] [Citation(s) in RCA: 20] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/07/2020] [Indexed: 12/18/2022]
Abstract
Regional anaesthesia in children has evolved rapidly in the last decade. Although it previously consisted of primarily neuraxial techniques, the practice now incorporates advanced peripheral nerve blocks, which were only recently described in adults. These novel blocks provide new avenues for providing opioid-sparing analgesia while minimising invasiveness, and perhaps risk, associated with older techniques. At the same time, established methods, such as infant spinal anaesthesia, under-utilised in the last 20 years, are experiencing a revival. The impetus has been the concern regarding the potential long-term neurocognitive effects of general anaesthesia in the young child. These techniques have expanded from single shot spinal anaesthesia to combined spinal/epidural techniques, which can now effectively provide surgical anaesthesia for procedures below the umbilicus for a prolonged period of time, thereby avoiding the need for general anaesthesia. Continuous 2-chloroprocaine infusions, previously only described for intra-operative regional anaesthesia, have gained popularity as a means of providing prolonged postoperative analgesia in epidural and continuous nerve block techniques. The rapid, liver-independent metabolism of 2-chloroprocaine makes it ideal for prolonged local anaesthetic infusions in neonates and small infants, obviating the increased risk of local anaesthetic systemic toxicity that occurs with amide local anaesthetics. Debate continues over certain practices in paediatric regional anaesthesia. While the rarity of complications makes comparative analyses difficult, data from large prospective registries indicate that providing regional anaesthesia to children while under general anaesthesia appears to be at least as safe as in the sedated or awake patient. In addition, the estimated frequency of serious adverse events demonstrates that regional blocks in children under general anaesthesia are no less safe than in awake adults. In infants, the techniques of direct thoracic epidural placement or caudal placement with cephalad threading each have distinct advantages and disadvantages. As the data cannot support the safety of one technique over the other, the site of epidural insertion remains largely a matter of anaesthetist discretion.
Collapse
Affiliation(s)
- G Heydinger
- Department of Anesthesiology and Pain Medicine, Nationwide Children's Hospital, Columbus, OH, USA
| | - J Tobias
- Department of Anesthesiology and Pain Medicine, Nationwide Children's Hospital, Columbus, OH, USA
| | - G Veneziano
- Department of Anesthesiology and Pain Medicine, Nationwide Children's Hospital, Columbus, OH, USA
| |
Collapse
|
7
|
Tobias J, Battin C, De Linhares AS, Lebens M, Baier K, Ambroz K, Högler S, Inic-Kanada A, Garner-Spitzer E, Preusser M, Kenner L, Kundi M, Zielinski C, Steinberger P, Wiedermann U. Active immunization with immune checkpoint inhibitors-mimotope elicits strong anti-tumour effect against HER-2/neu-expressing tumours. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz253.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
8
|
Zakeri K, Rotolo F, Lacas B, Vitzthum L, Le QT, Gregoire V, Overgaard J, Tobias J, Zackrisson B, Parmar M, Burtness B, Ghi M, Sanguineti G, O'Sullivan B, Fortpied C, Bourhis J, Shen H, Harris J, Pignon JP, Mell L. Predictor of effectiveness of treatment intensification on overall survival in head and neck cancer (HNC). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy287.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
9
|
Morrison A, Tumin D, Hayes D, Phelps C, Tobias J, Gajarski R, Nandi D. Pediatric Marginal Donor Hearts: National Use and Center-Specific Variability. J Heart Lung Transplant 2017. [DOI: 10.1016/j.healun.2017.01.190] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
10
|
Schaufler C, Lasky J, Lim B, Suzuki Y, Mallem D, Oyster M, Lederer D, Meyer K, Bermudez C, Tobias J, Van Deerlin V, Olthoff K, Shaked A, Diamond J, Cantu E, Christie J. Gene Set Enrichment Analysis Identifies a Potential Link Between Smoking and Upregulation of Olfactory Receptor and Cytokine Enrichment Pathways. J Heart Lung Transplant 2017. [DOI: 10.1016/j.healun.2017.01.1194] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
11
|
Petit C, Pignon J, Landais C, Trotti A, Gregoire V, Overgaard J, Tobias J, Zackrisson B, Parmar M, Lee J, Ghi M, Corvo R, Janot F, O'Sullivan B, Horiuchi M, Zhang Q, Fortpied C, Grau C, Bourhis J, Blanchard P. What is the most effective treatment for head and neck squamous cell carcinoma? An individual patient data network meta-analysis from the MACH-NC and MARCH collaborative groups. Eur J Cancer 2017. [DOI: 10.1016/s0959-8049(17)30415-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
12
|
Blanchard P, Landais C, Petit C, Zhang Q, Grégoire V, Tobias J, Burtness B, Ghi M, Janot F, Overgaard J, Wolf G, Lewin F, Hitt R, Corvo R, Budach V, Trotti A, Fortpied C, Hackshaw A, Bourhis J, Pignon JP. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 100 randomized trials and 19,248 patients, on behalf of MACH-NC group. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw376.02] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
13
|
Al-Sari UA, Tobias J, Clark E. Health-related quality of life in older people with osteoporotic vertebral fractures: a systematic review and meta-analysis. Osteoporos Int 2016; 27:2891-900. [PMID: 27262840 DOI: 10.1007/s00198-016-3648-x] [Citation(s) in RCA: 72] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/23/2016] [Accepted: 05/20/2016] [Indexed: 11/30/2022]
Abstract
Health-related quality of life in osteoporotic patients with vertebral fracture is of increasing interest, but relevant studies have yielded debatable results. This systematic review and meta-analysis of 16 observational studies demonstrate a clear association between physical health status and presence of vertebral fracture after accounting for age. This meta-analysis was conducted to identify if there are any differences between physical and/or mental health-related quality of life (HRQoL) in older people with osteoporosis based on conventional T-score definitions and the presence or absence of vertebral fracture. A comprehensive search was undertaken using the databases of PubMed, Embase, Medline, Web of Science, and the "grey" literature from 1950 to the end of April 2015. Search terms for vertebral fracture (VF) included VF, osteoporotic fracture, fragility fracture, and spinal fracture. Quality of life was searched using the following terms: quality of life, health-related quality of life, HRQoL, and QoL. Strict inclusion and exclusion criteria were used. The standardized mean difference (SMD) was calculated for each HRQoL domain by the difference in means between case and control groups divided by the pooled SD of participants. Sixteen eligible studies were identified involving 3131 men and women. There was evidence of publication bias and heterogeneity. The meta-analysis showed worse physical (SMD = 0.53, 95 % confidence interval (CI) 0.38 to 0.68; P < 0.001) and mental (SMD = 0.19, 95 % CI 0.05 to 0.33; P = 0.009) HRQoL in osteoporotic older people with vertebral fracture compared to those without fracture. Similar differences were observed for physical HRQoL in further analyses accounting for possible confounding effects of age. Sub-analysis to assess associations between number/severity of fractures and time since fracture was not possible due to small numbers of studies that accounted for age. Osteoporotic older people with vertebral fracture have worse physical HRQoL than osteoporotic older people without vertebral fracture, even after accounting for age differences.
Collapse
Affiliation(s)
- U A Al-Sari
- Academic Rheumatology, Musculoskeletal Research Unit, School of Clinical Sciences, University of Bristol, Southmead Hospital, Westbury-on-Trym, Bristol, BS10 5NB, UK
| | - J Tobias
- Academic Rheumatology, Musculoskeletal Research Unit, School of Clinical Sciences, University of Bristol, Southmead Hospital, Westbury-on-Trym, Bristol, BS10 5NB, UK
| | - E Clark
- Academic Rheumatology, Musculoskeletal Research Unit, School of Clinical Sciences, University of Bristol, Southmead Hospital, Westbury-on-Trym, Bristol, BS10 5NB, UK.
| |
Collapse
|
14
|
Diamond J, Cantu E, Lederer D, Tobias J, Arcasoy S, Olthoff K, Chang B, Feng R, Meyer K, Emond J, Shaked A, Christie J. PGD Is Associated With Persistent Differential Gene Expression After Lung Transplantation. J Heart Lung Transplant 2015. [DOI: 10.1016/j.healun.2015.01.464] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
15
|
Pitman JP, Wilkinson R, Basavaraju SV, von Finckenstein B, Sibinga CS, Marfin AA, Postma MJ, Mataranyika M, Tobias J, Lowrance DW. Investments in blood safety improve the availability of blood to underserved areas in a sub-Saharan African country. ACTA ACUST UNITED AC 2014; 9:325-333. [PMID: 26478742 DOI: 10.1111/voxs.12107] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
BACKGROUND AND OBJECTIVES Since 2004, several African countries, including Namibia, have received assistance from the U.S. President's Emergency Plan for AIDS Relief (PEPFAR). Gains have been documented in the safety and number of collected units in these countries, but the distribution of blood has not been described. MATERIALS AND METHODS Nine years of data on blood requests and issues from Namibia were stratified by region to describe temporal and spatial changes in the number and type of blood components issued to Namibian healthcare facilities nationally. RESULTS Between 2004 and 2007 (early years of PEPFAR support) and 2008-2011 (peak years of PEPFAR support), the average number of red cell units issued annually increased by 23.5% in seven densely populated but less-developed regions in northern Namibia; by 30% in two regions with urban centres; and by 35.1% in four sparsely populated rural regions. CONCLUSION Investments in blood safety and a policy decision to emphasize distribution of blood to underserved regions improved blood availability in remote rural areas and increased the proportion of units distributed as components. However, disparities persist in the distribution of blood between Namibia's urban and rural regions.
Collapse
Affiliation(s)
- J P Pitman
- Center for Global Health, Division of Global HIV/AIDS, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - R Wilkinson
- The Blood Transfusion Service of Namibia, Windhoek, Namibia
| | - S V Basavaraju
- Center for Global Health, Division of Global HIV/AIDS, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | | | | | - A A Marfin
- Center for Global Health, Division of Global HIV/AIDS, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - M J Postma
- Unit of PharmacoEpidemiology & PharmacoEconomics (PE2), Department of Pharmacy, University of Groningen, Groningen, Netherlands ; Institute of Science in Healthy Aging & health caRE (SHARE), University Medical Center Groningen (UMCG), Groningen, Netherlands
| | - M Mataranyika
- Directorate for Clinical Support Services, Ministry of Health and Social Services, Windhoek, Namibia
| | - J Tobias
- Center for Global Health, Division of Global HIV/AIDS, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - D W Lowrance
- Center for Global Health, Division of Global HIV/AIDS, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| |
Collapse
|
16
|
Vaidya J, Wenz F, Bulsara M, Massarut S, Tobias J, Williams N, Joseph D, Baum M. Omitting Whole Breast Radiation Therapy did not Increase Axillary Recurrence in the TARGIT-A Trial. Int J Radiat Oncol Biol Phys 2013. [DOI: 10.1016/j.ijrobp.2013.06.025] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
17
|
Vaidya J, Bulsara M, Wenz F, Massarut S, Joseph D, Tobias J, Williams N, Baum M. The Lower Non-Breast Cancer Mortality With TARGIT in the TARGIT-A Trial Could Be a Systemic Effect of TARGIT on Tumor Microenvironment. Int J Radiat Oncol Biol Phys 2013. [DOI: 10.1016/j.ijrobp.2013.06.623] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
18
|
Cornell P, Trehane A, Thompson P, Rahmeh F, Greenwood M, Baqai TJ, Cambridge S, Shaikh M, Rooney M, Donnelly S, Tahir H, Ryan S, Kamath S, Hassell A, McCuish WJ, Bearne L, Mackenzie-Green B, Price E, Williamson L, Collins D, Tang E, Hayes J, McLoughlin YM, Chamberlain V, Campbell S, Shah P, McKenna F, Cornell P, Westlake S, Thompson P, Richards S, Homer D, Gould E, Empson B, Kemp P, Richards AG, Walker J, Taylor S, Bari SF, Alachkar M, Rajak R, Lawson T, O'Sullivan M, Samant S, Butt S, Gadsby K, Flurey CA, Morris M, Hughes R, Pollock J, Richards P, Hewlett S, Edwards KR, Rowe I, Sanders T, Dunn K, Konstantinou K, Hay E, Jones LE, Adams J, White P, Donovan-Hall M, Hislop K, Barbosa Boucas S, Nichols VP, Williamson EM, Toye F, Lamb SE, Rodham K, Gavin J, Watts L, Coulson N, Diver C, Avis M, Gupta A, Ryan SJ, Stangroom S, Pearce JM, Byrne J, Manning VL, Hurley M, Scott DL, Choy E, Bearne L, Taylor J, Morris M, Dures E, Hewlett S, Wilson A, Adams J, Larkin L, Kennedy N, Gallagher S, Fraser AD, Shrestha P, Batley M, Koduri G, Scott DL, Flurey CA, Morris M, Hughes R, Pollock J, Richards P, Hewlett S, Kumar K, Raza K, Nightingale P, Horne R, Chapman S, Greenfield S, Gill P, Ferguson AM, Ibrahim F, Scott DL, Lempp H, Tierney M, Fraser A, Kennedy N, Barbosa Boucas S, Hislop K, Dziedzic K, Arden N, Burridge J, Hammond A, Stokes M, Lewis M, Gooberman-Hill R, Coales K, Adams J, Nutland H, Dean A, Laxminarayan R, Gates L, Bowen C, Arden N, Hermsen L, Terwee CB, Leone SS, vd Zwaard B, Smalbrugge M, Dekker J, vd Horst H, Wilkie R, Ferguson AM, Nicky Thomas V, Lempp H, Cope A, Scott DL, Simpson C, Weinman J, Agarwal S, Kirkham B, Patel A, Ibrahim F, Barn R, Brandon M, Rafferty D, Sturrock R, Turner D, Woodburn J, Rafferty D, Paul L, Marshall R, Gill J, McInnes I, Roderick Porter D, Woodburn J, Hennessy K, Woodburn J, Steultjens M, Siddle HJ, Hodgson RJ, Hensor EM, Grainger AJ, Redmond A, Wakefield RJ, Helliwell PS, Hammond A, Rayner J, Law RJ, Breslin A, Kraus A, Maddison P, Thom JM, Newcombe LW, Woodburn J, Porter D, Saunders S, McCarey D, Gupta M, Turner D, McGavin L, Freeburn R, Crilly A, Lockhart JC, Ferrell WR, Goodyear C, Ledingham J, Waterman T, Berkin L, Nicolaou M, Watson P, Lillicrap M, Birrell F, Mooney J, Merkel PA, Poland F, Spalding N, Grayson P, Leduc R, Shereff D, Richesson R, Watts RA, Roussou E, Thapper M, Bateman J, Allen M, Kidd J, Parsons N, Davies D, Watt KA, Scally MD, Bosworth A, Wilkinson K, Collins S, Jacklin CB, Ball SK, Grosart R, Marks J, Litwic AE, Sriranganathan MK, Mukherjee S, Khurshid MA, Matthews SM, Hall A, Sheeran T, Baskar S, Muether M, Mackenzie-Green B, Hetherington A, Wickrematilake G, Williamson L, Daniels LE, Gwynne CE, Khan A, Lawson T, Clunie G, Stephenson S, Gaffney K, Belsey J, Harvey NC, Clarke-Harris R, Murray R, Costello P, Garrett E, Holbrook J, Teh AL, Wong J, Dogra S, Barton S, Davies L, Inskip H, Hanson M, Gluckman P, Cooper C, Godfrey K, Lillycrop K, Anderton T, Clarke S, Rao Chaganti S, Viner N, Seymour R, Edwards MH, Parsons C, Ward K, Thompson J, Prentice A, Dennison E, Cooper C, Clark E, Cumming M, Morrison L, Gould VC, Tobias J, Holroyd CR, Winder N, Osmond C, Fall C, Barker D, Ring S, Lawlor D, Tobias J, Davey Smith G, Cooper C, Harvey NC, Toms TE, Afreedi S, Salt K, Roskell S, Passey K, Price T, Venkatachalam S, Sheeran T, Davies R, Southwood TR, Kearsley-Fleet L, Hyrich KL, Kingsbury D, Quartier P, Patel G, Arora V, Kupper H, Mozaffarian N, Kearsley-Fleet L, Baildam E, Beresford MW, Davies R, Foster HE, Mowbray K, Southwood TR, Thomson W, Hyrich KL, Saunders E, Baildam E, Chieng A, Davidson J, Foster H, Gardner-Medwin J, Wedderburn L, Thomson W, Hyrich K, McErlane F, Beresford M, Baildam E, Chieng SE, Davidson J, Foster HE, Gardner-Medwin J, Lunt M, Wedderburn L, Thomson W, Hyrich K, Rooney M, Finnegan S, Gibson DS, Borg FA, Bale PJ, Armon K, Cavelle A, Foster HE, McDonagh J, Bale PJ, Armon K, Wu Q, Pesenacker AM, Stansfield A, King D, Barge D, Abinun M, Foster HE, Wedderburn L, Stanley K, Morrissey D, Parsons S, Kuttikat A, Shenker N, Garrood T, Medley S, Ferguson AM, Keeling D, Duffort P, Irving K, Goulston L, Culliford D, Coakley P, Taylor P, Hart D, Spector T, Hakim A, Arden N, Mian A, Garrood T, Magan T, Chaudhary M, Lazic S, Sofat N, Thomas MJ, Moore A, Roddy E, Peat G, Rees F, Lanyon P, Jordan N, Chaib A, Sangle S, Tungekar F, Sabharwal T, Abbs I, Khamashta M, D'Cruz D, Dzifa Dey I, Isenberg DA, Chin CW, Cheung C, Ng M, Gao F, Qiong Huang F, Thao Le T, Yong Fong K, San Tan R, Yin Wong T, Julian T, Parker B, Al-Husain A, Yvonne Alexander M, Bruce I, Jordan N, Abbs I, D'cruz D, McDonald G, Miguel L, Hall C, Isenberg DA, Magee A, Butters T, Jury E, Yee CS, Toescu V, Hickman R, Leung MH, Situnayake D, Bowman S, Gordon C, Yee CS, Toescu V, Hickman R, Leung MH, Situnayake D, Bowman S, Gordon C, Lazarus MN, Isenberg DA, Ehrenstein M, Carter LM, Isenberg DA, Ehrenstein MR, Chanchlani N, Gayed M, Yee CS, Gordon C, Ball E, Rooney M, Bell A, Reynolds JA, Ray DW, O'Neill T, Alexander Y, Bruce I, Sutton EJ, Watson KD, Isenberg D, Rahman A, Gordon C, Yee CS, Lanyon P, Jayne D, Akil M, D'Cruz D, Khamashta M, Lutalo P, Erb N, Prabu A, Edwards CJ, Youssef H, McHugh N, Vital E, Amft N, Griffiths B, Teh LS, Zoma A, Bruce I, Durrani M, Jordan N, Sangle S, D'Cruz D, Pericleous C, Ruiz-Limon P, Romay-Penabad Z, Carrera-Marin A, Garza-Garcia A, Murfitt L, Driscoll PC, Giles IP, Ioannou Y, Rahman A, Pierangeli SS, Ripoll VM, Lambrianides A, Heywood WE, Ioannou J, Giles IP, Rahman A, Stevens C, Dures E, Morris M, Knowles S, Hewlett S, Marshall R, Reddy V, Croca S, Gerona D, De La Torre Ortega I, Isenberg DA, Leandro M, Cambridge G, Reddy V, Cambridge G, Isenberg DA, Glennie M, Cragg M, Leandro M, Croca SC, Isenberg DA, Giles I, Ioannou Y, Rahman A, Croca SC, Isenberg DA, Giles I, Ioannou Y, Rahman A, Artim Esen B, Pericleous C, MacKie I, Ioannou Y, Rahman A, Isenberg DA, Giles I, Skeoch S, Haque S, Pemberton P, Bruce I. BHPR: Audit and Clinical Evaluation * 103. Dental Health in Children and Young Adults with Inflammatory Arthritis: Access to Dental Care. Rheumatology (Oxford) 2013. [DOI: 10.1093/rheumatology/ket196] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
19
|
Karrar S, Shiwen X, Nikotorowicz-Buniak J, Abraham DJ, Denton C, Stratton R, Bayley R, Kite KA, Clay E, Smith JP, Kitas GD, Buckley C, Young SP, Ye L, Zhang L, Goodall J, Gaston H, Xu H, Lutalo PM, Zhao Y, Meng Choong L, Sangle S, Spencer J, D'Cruz D, Rysnik OJ, McHugh K, Bowness P, Rump-Goodrich L, Mattey D, Kehoe O, Middleton J, Cartwright A, Schmutz C, Askari A, Middleton J, Gardner DH, Jeffery LE, Raza K, Sansom DM, Clay E, Bayley R, Fitzpatrick M, Wallace G, Young S, Shaw J, Hatano H, Cauli A, Giles JL, McHugh K, Mathieu A, Bowness P, Kollnberger S, Webster S, Ellis L, O'Brien LM, Fitzmaurice TJ, Gaston H, Goodall J, Nazeer Moideen A, Evans L, Osgood L, Williams A, Jones S, Thomas C, O'Donnell V, Nowell M, Ouboussad L, Savic S, Dickie LJ, Hintze J, Wong CH, Cook GP, Buch M, Emery P, McDermott MF, Hardcastle SA, Gregson CL, Deere K, Davey Smith G, Dieppe P, Tobias JH, Dennison E, Edwards M, Bennett J, Coggon D, Palmer K, Cooper C, McWilliams D, Young A, Kiely PD, Walsh D, Taylor HJ, Harding I, Hutchinson J, Nelson I, Blom A, Tobias J, Clark E, Parker J, Bukhari M, McWilliams D, Jayakumar K, Young A, Kiely P, Walsh D, Diffin J, Lunt M, Marshall T, Chipping J, Symmons D, Verstappen S, Taylor HJ, Harding I, Hutchinson J, Nelson I, Tobias J, Clark E, Bluett J, Bowes J, Ho P, McHugh N, Buden D, Fitzgerald O, Barton A, Glossop JR, Nixon NB, Emes RD, Dawes PT, Farrell WE, Mattey DL, Scott IC, Steer S, Seegobin S, Hinks AM, Eyre S, Morgan A, Wilson AG, Hocking L, Wordsworth P, Barton A, Worthington J, Cope A, Lewis CM, Guerra S, Ahmed BA, Denton C, Abraham D, Fonseca C, Robinson J, Taylor J, Haroon Rashid L, Flynn E, Eyre S, Worthington J, Barton A, Isaacs J, Bowes J, Wilson AG, Barrett JH, Morgan A, Kingston B, Ahmed M, Kirwan JR, Marshall R, Chapman K, Pearson R, Heycock C, Kelly C, Rynne M, Saravanan V, Hamilton J, Saeed A, Coughlan R, Carey JJ, Farah Z, Matthews W, Bell C, Petford S, Tibbetts LM, Douglas KMJ, Holden W, Ledingham J, Fletcher M, Winfield R, Price Z, Mackay K, Dixon C, Oppong R, Jowett S, Nicholls E, Whitehurst D, Hill S, Hammond A, Hay E, Dziedzic K, Righetti C, Lebmeier M, Manning VL, Hurley M, Scott DL, Choy E, Bearne L, Nikiphorou E, Morris S, James D, Kiely P, Walsh D, Young A, Wong EC, Long J, Fletcher A, Fletcher M, Holmes S, Hockey P, Abbas M, Chattopadhyay C, Flint J, Gayed M, Schreiber K, Arthanari S, Nisar M, Khamashta M, Gordon C, Giles I, Robson J, Kiran A, Maskell J, Arden N, Hutchings A, Emin A, Culliford D, Dasgupta B, Hamilton W, Luqmani R, Jethwa H, Rowczenio D, Trojer H, Russell T, Loeffler J, Hawkins P, Lachmann H, Verma I, Syngle A, Krishan P, Garg N, Flint J, Gayed M, Schreiber K, Arthanari S, Nisar M, Khamashta M, Gordon C, Giles I, McGowan SP, Gerrard DT, Chinoy H, Ollier WE, Cooper RG, Lamb JA, Taborda L, Correia Azevedo P, Isenberg D, Leyland KM, Kiran A, Judge A, Hunter D, Hart D, Javaid MK, Arden N, Cooper C, Edwards MH, Litwic AE, Jameson KA, Deeg D, Cooper C, Dennison E, Edwards MH, Jameson KA, Cushnaghan J, Aihie Sayer A, Deeg D, Cooper C, Dennison E, Jagannath D, Parsons C, Cushnaghan J, Cooper C, Edwards MH, Dennison E, Stoppiello L, Mapp P, Ashraf S, Wilson D, Hill R, Scammell B, Walsh D, Wenham C, Shore P, Hodgson R, Grainger A, Aaron J, Hordon L, Conaghan P, Bar-Ziv Y, Beer Y, Ran Y, Benedict S, Halperin N, Drexler M, Mor A, Segal G, Lahad A, Haim A, Rath U, Morgensteren DM, Salai M, Elbaz A, Vasishta VG, Derrett-Smith E, Hoyles R, Khan K, Abraham DJ, Denton C, Ezeonyeji A, Takhar G, Denton C, Ong V, Loughrey L, Bissell LA, Hensor E, Abignano G, Redmond A, Buch M, Del Galdo F, Hall FC, Malaviya A, Nisar M, Baker S, Furlong A, Mitchell A, Godfrey AL, Ruddlesden M, Hadjinicolaou A, Hughes M, Moore T, O'Leary N, Tracey A, Ennis H, Dinsdale G, Roberts C, Herrick A, Denton CP, Guillevin L, Hunsche E, Rosenberg D, Schwierin B, Scott M, Krieg T, Anderson M, Hall FC, Herrick A, McHugh N, Matucci-Cerinic M, Alade R, Khan K, Xu S, Denton C, Ong V, Nihtyanova S, Ong V, Denton CP, Clark KE, Tam FWK, Unwin R, Khan K, Abraham DJ, Denton C, Stratton RJ, Nihtyanova S, Schreiber B, Ong V, Denton CP, Seng Edwin Lim C, Dasgupta B, Corsiero E, Sutcliffe N, Wardemann H, Pitzalis C, Bombardieri M, Tahir H, Donnelly S, Greenwood M, Smith TO, Easton V, Bacon H, Jerman E, Armon K, Poland F, Macgregor A, van der Heijde D, Sieper J, Elewaut D, Pangan AL, Nguyen D, Badenhorst C, Kirby S, White D, Harrison A, Garcia JA, Stebbings S, MacKay JW, Aboelmagd S, Gaffney K, van der Heijde D, Deodhar A, Braun J, Mack M, Hsu B, Gathany T, Han C, Inman RD, Cooper-Moss N, Packham J, Strauss V, Freeston JE, Coates L, Nam J, Moverley AR, Helliwell P, Hensor E, Wakefield R, Emery P, Conaghan P, Mease P, Fleischmann R, Wollenhaupt J, Deodhar A, Kielar D, Woltering F, Stach C, Hoepken B, Arledge T, van der Heijde D, Gladman D, Fleischmann R, Coteur G, Woltering F, Mease P, Kavanaugh A, Gladman D, van der Heijde D, Purcaru O, Mease P, McInnes I, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C, Li S, Wang Y, Mendelsohn A, Doyle M, Tillett W, Jadon D, Shaddick G, Cavill C, Robinson G, Sengupta R, Korendowych E, de Vries C, McHugh N, Thomas RC, Shuto T, Busquets-Perez N, Marzo-Ortega H, McGonagle D, Tillett W, Richards G, Cavill C, Sengupta R, Shuto T, Marzo-Ortega H, Thomas RC, Bingham S, Coates L, Emery P, John Hamlin P, Adshead R, Cambridge S, Donnelly S, Tahir H, Suppiah P, Cullinan M, Nolan A, Thompson WM, Stebbings S, Mathieson HR, Mackie SL, Bryer D, Buch M, Emery P, Marzo-Ortega H, Krutikov M, Gray L, Bruce E, Ho P, Marzo-Ortega H, Busquets-Perez N, Thomas RC, Gaffney K, Keat A, Innes W, Pandit R, Kay L, Lapshina S, Myasoutova L, Erdes S, Wallis D, Waldron N, McHugh N, Korendowych E, Thorne I, Harris C, Keat A, Garg N, Syngle A, Vohra K, Khinchi D, Verma I, Kaur L, Jones A, Harrison N, Harris D, Jones T, Rees J, Bennett A, Fazal S, Tugnet N, Barkham N, Basu N, McClean A, Harper L, Amft EN, Dhaun N, Luqmani RA, Little MA, Jayne DR, Flossmann O, McLaren J, Kumar V, Reid DM, Macfarlane GJ, Jones G, Yates M, Watts RA, Igali L, Mukhtyar C, Macgregor A, Robson J, Doll H, Yew S, Flossmann O, Suppiah R, Harper L, Hoglund P, Jayne D, Mukhtyar C, Westman K, Luqmani R, Win Maw W, Patil P, Williams M, Adizie T, Christidis D, Borg F, Dasgupta B, Robertson A, Croft AP, Smith S, Carr S, Youssouf S, Salama A, Pusey C, Harper L, Morgan M. Basic Science * 208. Stem Cell Factor Expression is Increased in the Skin of Patients with Systemic Sclerosis and Promotes Proliferation and Migration of Fibroblasts in vitro. Rheumatology (Oxford) 2013. [DOI: 10.1093/rheumatology/ket195] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
|
20
|
Tobias J, Deere K, Palmer S, Clark E, Clinch J, Fikree A, Aktar R, Wellstead G, Knowles C, Grahame R, Aziz Q, Amaral B, Murphy G, Ioannou Y, Isenberg DA, Tansley SL, Betteridge ZE, Gunawardena H, Shaddick G, Varsani H, Wedderburn L, McHugh N, De Benedetti F, Ruperto N, Espada G, Gerloni V, Flato B, Horneff G, Myones BL, Onel K, Frane J, Kenwright A, Lipman TH, Bharucha KN, Martini A, Lovell DJ, Baildam E, Ruperto N, Brunner H, Zuber Z, Keane C, Harari O, Kenwright A, Cuttica RJ, Keltsev V, Xavier R, Penades IC, Nikishina I, Rubio-Perez N, Alekseeva E, Chasnyk V, Chavez J, Horneff G, Opoka-Winiarska V, Quartier P, Silva CA, Silverman ED, Spindler A, Lovell DJ, Martini A, De Benedetti F, Hendry GJ, Watt GF, Brandon M, Friel L, Turner D, Lorgelly PK, Gardner-Medwin J, Sturrock RD, Woodburn J, Firth J, Waxman R, Law G, Siddle H, Nelson AE, Helliwell P, Otter S, Butters V, Loughrey L, Alcacer-Pitarch B, Tranter J, Davies S, Hryniw R, Lewis S, Baker L, Dures E, Hewlett S, Ambler N, Clarke J, Gooberman-Hill R, Jenkins R, Wilkie R, Bucknall M, Jordan K, McBeth J, Norton S, Walsh D, Kiely P, Williams R, Young A, Harkess JE, McAlarey K, Chesterton L, van der Windt DA, Sim J, Lewis M, Mallen CD, Mason E, Hay E, Clarson LE, Hider SL, Belcher J, Heneghan C, Roddy E, Mallen CD, Gibson J, Whiteford S, Williamson E, Beatty S, Hamilton-Dyer N, Healey EL, Ryan S, McHugh GA, Main CJ, Porcheret M, Nio Ong B, Pushpa-Rajah A, Dziedzic KS, MacRae CS, Shortland A, Lewis J, Morrissey M, Critchley D, Muller S, Mallen CD, Belcher J, Helliwell T, Hider SL, Cole Z, Parsons C, Crozier S, Robinson S, Taylor P, Inskip H, Godfrey K, Dennison E, Harvey NC, Cooper C, Prieto Alhambra D, Lalmohamed A, Abrahamsen B, Arden N, de Boer A, Vestergaard P, de Vries F, Kendal A, Carr A, Prieto-Alhambra D, Judge A, Cooper C, Chapurlat R, Bellamy N, Czerwinski E, Pierre Devogelaer J, March L, Pavelka K, Reginster JY, Kiran A, Judge A, Javaid MK, Arden N, Cooper C, Sundy JS, Baraf HS, Becker M, Treadwell EL, Yood R, Ottery FD. Oral Abstracts 3: Adolescent and Young Adult * O13. Hypermobility is a Risk Factor for Musculoskeletal Pain in Adolescence: Findings From a Prospective Cohort Study. Rheumatology (Oxford) 2013. [DOI: 10.1093/rheumatology/ket200] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
21
|
Tobias J, Vaidya J. OC-0236: The TARGIT-A trial of intra-operative radiotherapy for breast cancer: Updated recurrence and survival. Radiother Oncol 2013. [DOI: 10.1016/s0167-8140(15)32542-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
22
|
Lundgren A, Leach S, Tobias J, Carlin N, Gustafsson B, Jertborn M, Bourgeois L, Walker R, Holmgren J, Svennerholm AM. Clinical trial to evaluate safety and immunogenicity of an oral inactivated enterotoxigenic Escherichia coli prototype vaccine containing CFA/I overexpressing bacteria and recombinantly produced LTB/CTB hybrid protein. Vaccine 2013; 31:1163-70. [DOI: 10.1016/j.vaccine.2012.12.063] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2012] [Revised: 12/18/2012] [Accepted: 12/26/2012] [Indexed: 11/30/2022]
|
23
|
Aad G, Abbott B, Abdallah J, Abdelalim AA, Abdesselam A, Abdinov O, Abi B, Abolins M, Abramowicz H, Abreu H, Acerbi E, Acharya BS, Adams DL, Addy TN, Adelman J, Aderholz M, Adomeit S, Adragna P, Adye T, Aefsky S, Aguilar-Saavedra JA, Aharrouche M, Ahlen SP, Ahles F, Ahmad A, Ahsan M, Aielli G, Akdogan T, Akesson TPA, Akimoto G, Akimov AV, Akiyama A, Alam MS, Alam MA, Albert J, Albrand S, Aleksa M, Aleksandrov IN, Alessandria F, Alexa C, Alexander G, Alexandre G, Alexopoulos T, Alhroob M, Aliev M, Alimonti G, Alison J, Aliyev M, Allport PP, Allwood-Spiers SE, Almond J, Aloisio A, Alon R, Alonso A, Alvarez Gonzalez B, Alviggi MG, Amako K, Amaral P, Amelung C, Ammosov VV, Amorim A, Amorós G, Amram N, Anastopoulos C, Ancu LS, Andari N, Andeen T, Anders CF, Anders G, Anderson KJ, Andreazza A, Andrei V, Andrieux ML, Anduaga XS, Angerami A, Anghinolfi F, Anjos N, Annovi A, Antonaki A, Antonelli M, Antonov A, Antos J, Anulli F, Aoun S, Aperio Bella L, Apolle R, Arabidze G, Aracena I, Arai Y, Arce ATH, Archambault JP, Arfaoui S, Arguin JF, Arik E, Arik M, Armbruster AJ, Arnaez O, Artamonov A, Artoni G, Arutinov D, Asai S, Asfandiyarov R, Ask S, Asman B, Asquith L, Assamagan K, Astbury A, Astvatsatourov A, Atoian G, Aubert B, Auge E, Augsten K, Aurousseau M, Avolio G, Avramidou R, Axen D, Ay C, Azuelos G, Azuma Y, Baak MA, Baccaglioni G, Bacci C, Bach AM, Bachacou H, Bachas K, Bachy G, Backes M, Backhaus M, Badescu E, Bagnaia P, Bahinipati S, Bai Y, Bailey DC, Bain T, Baines JT, Baker OK, Baker MD, Baker S, Banas E, Banerjee P, Banerjee S, Banfi D, Bangert A, Bansal V, Bansil HS, Barak L, Baranov SP, Barashkou A, Barbaro Galtieri A, Barber T, Barberio EL, Barberis D, Barbero M, Bardin DY, Barillari T, Barisonzi M, Barklow T, Barlow N, Barnett BM, Barnett RM, Baroncelli A, Barone G, Barr AJ, Barreiro F, Barreiro Guimarães da Costa J, Bartoldus R, Barton AE, Bartsch V, Bates RL, Batkova L, Batley JR, Battaglia A, Battistin M, Battistoni G, Bauer F, Bawa HS, Beare B, Beau T, Beauchemin PH, Beccherle R, Bechtle P, Beck HP, Becker S, Beckingham M, Becks KH, Beddall AJ, Beddall A, Bedikian S, Bednyakov VA, Bee CP, Begel M, Behar Harpaz S, Behera PK, Beimforde M, Belanger-Champagne C, Bell PJ, Bell WH, Bella G, Bellagamba L, Bellina F, Bellomo M, Belloni A, Beloborodova O, Belotskiy K, Beltramello O, Ben Ami S, Benary O, Benchekroun D, Benchouk C, Bendel M, Benekos N, Benhammou Y, Benjamin DP, Benoit M, Bensinger JR, Benslama K, Bentvelsen S, Berge D, Bergeaas Kuutmann E, Berger N, Berghaus F, Berglund E, Beringer J, Bernat P, Bernhard R, Bernius C, Berry T, Bertin A, Bertinelli F, Bertolucci F, Besana MI, Besson N, Bethke S, Bhimji W, Bianchi RM, Bianco M, Biebel O, Bieniek SP, Bierwagen K, Biesiada J, Biglietti M, Bilokon H, Bindi M, Binet S, Bingul A, Bini C, Biscarat C, Bitenc U, Black KM, Blair RE, Blanchard JB, Blanchot G, Blazek T, Blocker C, Blocki J, Blondel A, Blum W, Blumenschein U, Bobbink GJ, Bobrovnikov VB, Bocchetta SS, Bocci A, Boddy CR, Boehler M, Boek J, Boelaert N, Böser S, Bogaerts JA, Bogdanchikov A, Bogouch A, Bohm C, Boisvert V, Bold T, Boldea V, Bolnet NM, Bona M, Bondarenko VG, Bondioli M, Boonekamp M, Boorman G, Booth CN, Bordoni S, Borer C, Borisov A, Borissov G, Borjanovic I, Borroni S, Bos K, Boscherini D, Bosman M, Boterenbrood H, Botterill D, Bouchami J, Boudreau J, Bouhova-Thacker EV, Bourdarios C, Bousson N, Boveia A, Boyd J, Boyko IR, Bozhko NI, Bozovic-Jelisavcic I, Bracinik J, Braem A, Branchini P, Brandenburg GW, Brandt A, Brandt G, Brandt O, Bratzler U, Brau B, Brau JE, Braun HM, Brelier B, Bremer J, Brenner R, Bressler S, Breton D, Britton D, Brochu FM, Brock I, Brock R, Brodbeck TJ, Brodet E, Broggi F, Bromberg C, Brooijmans G, Brooks WK, Brown G, Brown H, Bruckman de Renstrom PA, Bruncko D, Bruneliere R, Brunet S, Bruni A, Bruni G, Bruschi M, Buanes T, Bucci F, Buchanan J, Buchanan NJ, Buchholz P, Buckingham RM, Buckley AG, Buda SI, Budagov IA, Budick B, Büscher V, Bugge L, Buira-Clark D, Bulekov O, Bunse M, Buran T, Burckhart H, Burdin S, Burgess T, Burke S, Busato E, Bussey P, Buszello CP, Butin F, Butler B, Butler JM, Buttar CM, Butterworth JM, Buttinger W, Cabrera Urbán S, Caforio D, Cakir O, Calafiura P, Calderini G, Calfayan P, Calkins R, Caloba LP, Caloi R, Calvet D, Calvet S, Camacho Toro R, Camarri P, Cambiaghi M, Cameron D, Caminada LM, Campana S, Campanelli M, Canale V, Canelli F, Canepa A, Cantero J, Capasso L, Capeans Garrido MDM, Caprini I, Caprini M, Capriotti D, Capua M, Caputo R, Cardarelli R, Carli T, Carlino G, Carminati L, Caron B, Caron S, Carrillo Montoya GD, Carter AA, Carter JR, Carvalho J, Casadei D, Casado MP, Cascella M, Caso C, Castaneda Hernandez AM, Castaneda-Miranda E, Castillo Gimenez V, Castro NF, Cataldi G, Cataneo F, Catinaccio A, Catmore JR, Cattai A, Cattani G, Caughron S, Cauz D, Cavalleri P, Cavalli D, Cavalli-Sforza M, Cavasinni V, Ceradini F, Cerqueira AS, Cerri A, Cerrito L, Cerutti F, Cetin SA, Cevenini F, Chafaq A, Chakraborty D, Chan K, Chapleau B, Chapman JD, Chapman JW, Chareyre E, Charlton DG, Chavda V, Chavez Barajas CA, Cheatham S, Chekanov S, Chekulaev SV, Chelkov GA, Chelstowska MA, Chen C, Chen H, Chen S, Chen T, Chen X, Cheng S, Cheplakov A, Chepurnov VF, Cherkaoui El Moursli R, Chernyatin V, Cheu E, Cheung SL, Chevalier L, Chiefari G, Chikovani L, Childers JT, Chilingarov A, Chiodini G, Chizhov MV, Choudalakis G, Chouridou S, Christidi IA, Christov A, Chromek-Burckhart D, Chu ML, Chudoba J, Ciapetti G, Ciba K, Ciftci AK, Ciftci R, Cinca D, Cindro V, Ciobotaru MD, Ciocca C, Ciocio A, Cirilli M, Ciubancan M, Clark A, Clark PJ, Cleland W, Clemens JC, Clement B, Clement C, Clifft RW, Coadou Y, Cobal M, Coccaro A, Cochran J, Coe P, Cogan JG, Coggeshall J, Cogneras E, Cojocaru CD, Colas J, Colijn AP, Collard C, Collins NJ, Collins-Tooth C, Collot J, Colon G, Conde Muiño P, Coniavitis E, Conidi MC, Consonni M, Consorti V, Constantinescu S, Conta C, Conventi F, Cook J, Cooke M, Cooper BD, Cooper-Sarkar AM, Copic K, Cornelissen T, Corradi M, Corriveau F, Cortes-Gonzalez A, Cortiana G, Costa G, Costa MJ, Costanzo D, Costin T, Côté D, Courneyea L, Cowan G, Cowden C, Cox BE, Cranmer K, Crescioli F, Cristinziani M, Crosetti G, Crupi R, Crépé-Renaudin S, Cuciuc CM, Cuenca Almenar C, Cuhadar Donszelmann T, Curatolo M, Curtis CJ, Cwetanski P, Czirr H, Czyczula Z, D'Auria S, D'Onofrio M, D'Orazio A, Da Silva PVM, Da Via C, Dabrowski W, Dai T, Dallapiccola C, Dam M, Dameri M, Damiani DS, Danielsson HO, Dannheim D, Dao V, Darbo G, Darlea GL, Daum C, Davidek T, Davidson N, Davidson R, Davies E, Davies M, Davison AR, Davygora Y, Dawe E, Dawson I, Dawson JW, Daya RK, De K, de Asmundis R, De Castro S, De Castro Faria Salgado PE, De Cecco S, de Graat J, De Groot N, de Jong P, De La Taille C, De la Torre H, De Lotto B, De Mora L, De Nooij L, De Pedis D, De Salvo A, De Sanctis U, De Santo A, De Vivie De Regie JB, Dean S, Debbe R, Debenedetti C, Dedovich DV, Degenhardt J, Dehchar M, Del Papa C, Del Peso J, Del Prete T, Delemontex T, Deliyergiyev M, Dell'acqua A, Dell'Asta L, Della Pietra M, della Volpe D, Delmastro M, Delruelle N, Delsart PA, Deluca C, Demers S, Demichev M, Demirkoz B, Deng J, Denisov SP, Derendarz D, Derkaoui JE, Derue F, Dervan P, Desch K, Devetak E, Deviveiros PO, Dewhurst A, Dewilde B, Dhaliwal S, Dhullipudi R, Di Ciaccio A, Di Ciaccio L, Di Girolamo A, Di Girolamo B, Di Luise S, Di Mattia A, Di Micco B, Di Nardo R, Di Simone A, Di Sipio R, Diaz MA, Diblen F, Diehl EB, Dietrich J, Dietzsch TA, Dindar Yagci K, Dingfelder J, Dionisi C, Dita P, Dita S, Dittus F, Djama F, Djobava T, do Vale MAB, Do Valle Wemans A, Doan TKO, Dobbs M, Dobinson R, Dobos D, Dobson E, Dobson M, Dodd J, Doglioni C, Doherty T, Doi Y, Dolejsi J, Dolenc I, Dolezal Z, Dolgoshein BA, Dohmae T, Donadelli M, Donega M, Donini J, Dopke J, Doria A, Dos Anjos A, Dosil M, Dotti A, Dova MT, Dowell JD, Doxiadis AD, Doyle AT, Drasal Z, Drees J, Dressnandt N, Drevermann H, Driouichi C, Dris M, Dubbert J, Dube S, Duchovni E, Duckeck G, Dudarev A, Dudziak F, Dührssen M, Duerdoth IP, Duflot L, Dufour MA, Dunford M, Duran Yildiz H, Duxfield R, Dwuznik M, Dydak F, Düren M, Ebenstein WL, Ebke J, Eckweiler S, Edmonds K, Edwards CA, Edwards NC, Ehrenfeld W, Ehrich T, Eifert T, Eigen G, Einsweiler K, Eisenhandler E, Ekelof T, El Kacimi M, Ellert M, Elles S, Ellinghaus F, Ellis K, Ellis N, Elmsheuser J, Elsing M, Emeliyanov D, Engelmann R, Engl A, Epp B, Eppig A, Erdmann J, Ereditato A, Eriksson D, Ernst J, Ernst M, Ernwein J, Errede D, Errede S, Ertel E, Escalier M, Escobar C, Espinal Curull X, Esposito B, Etienne F, Etienvre AI, Etzion E, Evangelakou D, Evans H, Fabbri L, Fabre C, Fakhrutdinov RM, Falciano S, Fang Y, Fanti M, Farbin A, Farilla A, Farley J, Farooque T, Farrington SM, Farthouat P, Fassnacht P, Fassouliotis D, Fatholahzadeh B, Favareto A, Fayard L, Fazio S, Febbraro R, Federic P, Fedin OL, Fedorko W, Fehling-Kaschek M, Feligioni L, Feng C, Feng EJ, Fenyuk AB, Ferencei J, Ferland J, Fernando W, Ferrag S, Ferrando J, Ferrara V, Ferrari A, Ferrari P, Ferrari R, Ferrer A, Ferrer ML, Ferrere D, Ferretti C, Ferretto Parodi A, Fiascaris M, Fiedler F, Filipčič A, Filippas A, Filthaut F, Fincke-Keeler M, Fiolhais MCN, Fiorini L, Firan A, Fischer G, Fischer P, Fisher MJ, Flechl M, Fleck I, Fleckner J, Fleischmann P, Fleischmann S, Flick T, Flores Castillo LR, Flowerdew MJ, Fokitis M, Fonseca Martin T, Forbush DA, Formica A, Forti A, Fortin D, Foster JM, Fournier D, Foussat A, Fowler AJ, Fowler K, Fox H, Francavilla P, Franchino S, Francis D, Frank T, Franklin M, Franz S, Fraternali M, Fratina S, French ST, Friedrich F, Froeschl R, Froidevaux D, Frost JA, Fukunaga C, Fullana Torregrosa E, Fuster J, Gabaldon C, Gabizon O, Gadfort T, Gadomski S, Gagliardi G, Gagnon P, Galea C, Gallas EJ, Gallo V, Gallop BJ, Gallus P, Gan KK, Gao YS, Gapienko VA, Gaponenko A, Garberson F, Garcia-Sciveres M, García C, García Navarro JE, Gardner RW, Garelli N, Garitaonandia H, Garonne V, Garvey J, Gatti C, Gaudio G, Gaumer O, Gaur B, Gauthier L, Gavrilenko IL, Gay C, Gaycken G, Gayde JC, Gazis EN, Ge P, Gee CNP, Geerts DAA, Geich-Gimbel C, Gellerstedt K, Gemme C, Gemmell A, Genest MH, Gentile S, George M, George S, Gerlach P, Gershon A, Geweniger C, Ghazlane H, Ghez P, Ghodbane N, Giacobbe B, Giagu S, Giakoumopoulou V, Giangiobbe V, Gianotti F, Gibbard B, Gibson A, Gibson SM, Gilbert LM, Gilewsky V, Gillberg D, Gillman AR, Gingrich DM, Ginzburg J, Giokaris N, Giordani MP, Giordano R, Giorgi FM, Giovannini P, Giraud PF, Giugni D, Giunta M, Giusti P, Gjelsten BK, Gladilin LK, Glasman C, Glatzer J, Glazov A, Glitza KW, Glonti GL, Godfrey J, Godlewski J, Goebel M, Göpfert T, Goeringer C, Gössling C, Göttfert T, Goldfarb S, Golling T, Golovnia SN, Gomes A, Gomez Fajardo LS, Gonçalo R, Goncalves Pinto Firmino Da Costa J, Gonella L, Gonidec A, Gonzalez S, González de la Hoz S, Gonzalez Parra G, Gonzalez Silva ML, Gonzalez-Sevilla S, Goodson JJ, Goossens L, Gorbounov PA, Gordon HA, Gorelov I, Gorfine G, Gorini B, Gorini E, Gorišek A, Gornicki E, Gorokhov SA, Goryachev VN, Gosdzik B, Gosselink M, Gostkin MI, Gough Eschrich I, Gouighri M, Goujdami D, Goulette MP, Goussiou AG, Goy C, Gozpinar S, Grabowska-Bold I, Grafström P, Grahn KJ, Grancagnolo F, Grancagnolo S, Grassi V, Gratchev V, Grau N, Gray HM, Gray JA, Graziani E, Grebenyuk OG, Greenshaw T, Greenwood ZD, Gregersen K, Gregor IM, Grenier P, Griffiths J, Grigalashvili N, Grillo AA, Grinstein S, Grishkevich YV, Grivaz JF, Groh M, Gross E, Grosse-Knetter J, Groth-Jensen J, Grybel K, Guarino VJ, Guest D, Guicheney C, Guida A, Guillemin T, Guindon S, Guler H, Gunther J, Guo B, Guo J, Gupta A, Gusakov Y, Gushchin VN, Gutierrez A, Gutierrez P, Guttman N, Gutzwiller O, Guyot C, Gwenlan C, Gwilliam CB, Haas A, Haas S, Haber C, Hackenburg R, Hadavand HK, Hadley DR, Haefner P, Hahn F, Haider S, Hajduk Z, Hakobyan H, Haller J, Hamacher K, Hamal P, Hamer M, Hamilton A, Hamilton S, Han H, Han L, Hanagaki K, Hanawa K, Hance M, Handel C, Hanke P, Hansen JR, Hansen JB, Hansen JD, Hansen PH, Hansson P, Hara K, Hare GA, Harenberg T, Harkusha S, Harper D, Harrington RD, Harris OM, Harrison K, Hartert J, Hartjes F, Haruyama T, Harvey A, Hasegawa S, Hasegawa Y, Hassani S, Hatch M, Hauff D, Haug S, Hauschild M, Hauser R, Havranek M, Hawes BM, Hawkes CM, Hawkings RJ, Hawkins D, Hayakawa T, Hayashi T, Hayden D, Hayward HS, Haywood SJ, Hazen E, He M, Head SJ, Hedberg V, Heelan L, Heim S, Heinemann B, Heisterkamp S, Helary L, Hellman S, Hellmich D, Helsens C, Henderson RCW, Henke M, Henrichs A, Henriques Correia AM, Henrot-Versille S, Henry-Couannier F, Hensel C, Henß T, Hernandez CM, Hernández Jiménez Y, Herrberg R, Hershenhorn AD, Herten G, Hertenberger R, Hervas L, Hessey NP, Higón-Rodriguez E, Hill D, Hill JC, Hill N, Hiller KH, Hillert S, Hillier SJ, Hinchliffe I, Hines E, Hirose M, Hirsch F, Hirschbuehl D, Hobbs J, Hod N, Hodgkinson MC, Hodgson P, Hoecker A, Hoeferkamp MR, Hoffman J, Hoffmann D, Hohlfeld M, Holder M, Holmgren SO, Holy T, Holzbauer JL, Homma Y, Hong TM, Hooft van Huysduynen L, Horazdovsky T, Horn C, Horner S, Horton K, Hostachy JY, Hou S, Houlden MA, Hoummada A, Howarth J, Howell DF, Hristova I, Hrivnac J, Hruska I, Hryn'ova T, Hsu PJ, Hsu SC, Huang GS, Hubacek Z, Hubaut F, Huegging F, Huffman TB, Hughes EW, Hughes G, Hughes-Jones RE, Huhtinen M, Hurst P, Hurwitz M, Husemann U, Huseynov N, Huston J, Huth J, Iacobucci G, Iakovidis G, Ibbotson M, Ibragimov I, Ichimiya R, Iconomidou-Fayard L, Idarraga J, Iengo P, Igonkina O, Ikegami Y, Ikeno M, Ilchenko Y, Iliadis D, Imbault D, Imori M, Ince T, Inigo-Golfin J, Ioannou P, Iodice M, Irles Quiles A, Isaksson C, Ishikawa A, Ishino M, Ishmukhametov R, Issever C, Istin S, Ivashin AV, Iwanski W, Iwasaki H, Izen JM, Izzo V, Jackson B, Jackson JN, Jackson P, Jaekel MR, Jain V, Jakobs K, Jakobsen S, Jakubek J, Jana DK, Jankowski E, Jansen E, Jantsch A, Janus M, Jarlskog G, Jeanty L, Jelen K, Jen-La Plante I, Jenni P, Jeremie A, Jež P, Jézéquel S, Jha MK, Ji H, Ji W, Jia J, Jiang Y, Jimenez Belenguer M, Jin G, Jin S, Jinnouchi O, Joergensen MD, Joffe D, Johansen LG, Johansen M, Johansson KE, Johansson P, Johnert S, Johns KA, Jon-And K, Jones G, Jones RWL, Jones TW, Jones TJ, Jonsson O, Joram C, Jorge PM, Joseph J, Jovin T, Ju X, Jung CA, Juranek V, Jussel P, Juste Rozas A, Kabachenko VV, Kabana S, Kaci M, Kaczmarska A, Kadlecik P, Kado M, Kagan H, Kagan M, Kaiser S, Kajomovitz E, Kalinin S, Kalinovskaya LV, Kama S, Kanaya N, Kaneda M, Kanno T, Kantserov VA, Kanzaki J, Kaplan B, Kapliy A, Kaplon J, Kar D, Karagoz M, Karnevskiy M, Karr K, Kartvelishvili V, Karyukhin AN, Kashif L, Kasieczka G, Kasmi A, Kass RD, Kastanas A, Kataoka M, Kataoka Y, Katsoufis E, Katzy J, Kaushik V, Kawagoe K, Kawamoto T, Kawamura G, Kayl MS, Kazanin VA, Kazarinov MY, Keates JR, Keeler R, Kehoe R, Keil M, Kekelidze GD, Kennedy J, Kenney CJ, Kenyon M, Kepka O, Kerschen N, Kerševan BP, Kersten S, Kessoku K, Keung J, Khakzad M, Khalil-Zada F, Khandanyan H, Khanov A, Kharchenko D, Khodinov A, Kholodenko AG, Khomich A, Khoo TJ, Khoriauli G, Khoroshilov A, Khovanskiy N, Khovanskiy V, Khramov E, Khubua J, Kim H, Kim MS, Kim PC, Kim SH, Kimura N, Kind O, King BT, King M, King RSB, Kirk J, Kirsch LE, Kiryunin AE, Kishimoto T, Kisielewska D, Kittelmann T, Kiver AM, Kladiva E, Klaiber-Lodewigs J, Klein M, Klein U, Kleinknecht K, Klemetti M, Klier A, Klimentov A, Klingenberg R, Klinkby EB, Klioutchnikova T, Klok PF, Klous S, Kluge EE, Kluge T, Kluit P, Kluth S, Knecht NS, Kneringer E, Knobloch J, Knoops EBFG, Knue A, Ko BR, Kobayashi T, Kobel M, Kocian M, Kodys P, Köneke K, König AC, Koenig S, Köpke L, Koetsveld F, Koevesarki P, Koffas T, Koffeman E, Kohn F, Kohout Z, Kohriki T, Koi T, Kokott T, Kolachev GM, Kolanoski H, Kolesnikov V, Koletsou I, Koll J, Kollar D, Kollefrath M, Kolya SD, Komar AA, Komori Y, Kondo T, Kono T, Kononov AI, Konoplich R, Konstantinidis N, Kootz A, Koperny S, Kopikov SV, Korcyl K, Kordas K, Koreshev V, Korn A, Korol A, Korolkov I, Korolkova EV, Korotkov VA, Kortner O, Kortner S, Kostyukhin VV, Kotamäki MJ, Kotov S, Kotov VM, Kotwal A, Kourkoumelis C, Kouskoura V, Koutsman A, Kowalewski R, Kowalski TZ, Kozanecki W, Kozhin AS, Kral V, Kramarenko VA, Kramberger G, Krasny MW, Krasznahorkay A, Kraus J, Kraus JK, Kreisel A, Krejci F, Kretzschmar J, Krieger N, Krieger P, Kroeninger K, Kroha H, Kroll J, Kroseberg J, Krstic J, Kruchonak U, Krüger H, Kruker T, Krumshteyn ZV, Kruth A, Kubota T, Kuehn S, Kugel A, Kuhl T, Kuhn D, Kukhtin V, Kulchitsky Y, Kuleshov S, Kummer C, Kuna M, Kundu N, Kunkle J, Kupco A, Kurashige H, Kurata M, Kurochkin YA, Kus V, Kuze M, Kvita J, Kwee R, La Rosa A, La Rotonda L, Labarga L, Labbe J, Lablak S, Lacasta C, Lacava F, Lacker H, Lacour D, Lacuesta VR, Ladygin E, Lafaye R, Laforge B, Lagouri T, Lai S, Laisne E, Lamanna M, Lampen CL, Lampl W, Lancon E, Landgraf U, Landon MPJ, Landsman H, Lane JL, Lange C, Lankford AJ, Lanni F, Lantzsch K, Laplace S, Lapoire C, Laporte JF, Lari T, Larionov AV, Larner A, Lasseur C, Lassnig M, Laurelli P, Lavrijsen W, Laycock P, Lazarev AB, Le Dortz O, Le Guirriec E, Le Maner C, Le Menedeu E, Lebel C, Lecompte T, Ledroit-Guillon F, Lee H, Lee JSH, Lee SC, Lee L, Lefebvre M, Legendre M, Leger A, Legeyt BC, Legger F, Leggett C, Lehmacher M, Lehmann Miotto G, Lei X, Leite MAL, Leitner R, Lellouch D, Leltchouk M, Lemmer B, Lendermann V, Leney KJC, Lenz T, Lenzen G, Lenzi B, Leonhardt K, Leontsinis S, Leroy C, Lessard JR, Lesser J, Lester CG, Leung Fook Cheong A, Levêque J, Levin D, Levinson LJ, Levitski MS, Lewis A, Lewis GH, Leyko AM, Leyton M, Li B, Li H, Li S, Li X, Liang Z, Liang Z, Liao H, Liberti B, Lichard P, Lichtnecker M, Lie K, Liebig W, Lifshitz R, Lilley JN, Limbach C, Limosani A, Limper M, Lin SC, Linde F, Linnemann JT, Lipeles E, Lipinsky L, Lipniacka A, Liss TM, Lissauer D, Lister A, Litke AM, Liu C, Liu D, Liu H, Liu JB, Liu M, Liu S, Liu Y, Livan M, Livermore SSA, Lleres A, Llorente Merino J, Lloyd SL, Lobodzinska E, Loch P, Lockman WS, Loddenkoetter T, Loebinger FK, Loginov A, Loh CW, Lohse T, Lohwasser K, Lokajicek M, Loken J, Lombardo VP, Long RE, Lopes L, Lopez Mateos D, Losada M, Loscutoff P, Lo Sterzo F, Losty MJ, Lou X, Lounis A, Loureiro KF, Love J, Love PA, Lowe AJ, Lu F, Lubatti HJ, Luci C, Lucotte A, Ludwig A, Ludwig D, Ludwig I, Ludwig J, Luehring F, Luijckx G, Lumb D, Luminari L, Lund E, Lund-Jensen B, Lundberg B, Lundberg J, Lundquist J, Lungwitz M, Lutz G, Lynn D, Lys J, Lytken E, Ma H, Ma LL, Macana Goia JA, Maccarrone G, Macchiolo A, Maček B, Machado Miguens J, Mackeprang R, Madaras RJ, Mader WF, Maenner R, Maeno T, Mättig P, Mättig S, Magnoni L, Magradze E, Mahalalel Y, Mahboubi K, Mahout G, Maiani C, Maidantchik C, Maio A, Majewski S, Makida Y, Makovec N, Mal P, Malecki P, Malecki P, Maleev VP, Malek F, Mallik U, Malon D, Malone C, Maltezos S, Malyshev V, Malyukov S, Mameghani R, Mamuzic J, Manabe A, Mandelli L, Mandić I, Mandrysch R, Maneira J, Mangeard PS, Manjavidze ID, Mann A, Manning PM, Manousakis-Katsikakis A, Mansoulie B, Manz A, Mapelli A, Mapelli L, March L, Marchand JF, Marchese F, Marchiori G, Marcisovsky M, Marin A, Marino CP, Marroquim F, Marshall R, Marshall Z, Martens FK, Marti-Garcia S, Martin AJ, Martin B, Martin B, Martin FF, Martin JP, Martin P, Martin TA, Martin VJ, Martin Dit Latour B, Martin-Haugh S, Martinez M, Martinez Outschoorn V, Martyniuk AC, Marx M, Marzano F, Marzin A, Masetti L, Mashimo T, Mashinistov R, Masik J, Maslennikov AL, Massa I, Massaro G, Massol N, Mastrandrea P, Mastroberardino A, Masubuchi T, Mathes M, Matsumoto H, Matsunaga H, Matsushita T, Mattravers C, Maugain JM, Maurer J, Maxfield SJ, Maximov DA, May EN, Mayne A, Mazini R, Mazur M, Mazzanti M, Mazzoni E, Mc Kee SP, McCarn A, McCarthy RL, McCarthy TG, McCubbin NA, McFarlane KW, McFayden JA, McGlone H, McHedlidze G, McLaren RA, McLaughlan T, McMahon SJ, McPherson RA, Meade A, Mechnich J, Mechtel M, Medinnis M, Meera-Lebbai R, Meguro T, Mehdiyev R, Mehlhase S, Mehta A, Meier K, Meirose B, Melachrinos C, Mellado Garcia BR, Mendoza Navas L, Meng Z, Mengarelli A, Menke S, Menot C, Meoni E, Mercurio KM, Mermod P, Merola L, Meroni C, Merritt FS, Messina A, Metcalfe J, Mete AS, Meyer C, Meyer C, Meyer JP, Meyer J, Meyer J, Meyer TC, Meyer WT, Miao J, Michal S, Micu L, Middleton RP, Miele P, Migas S, Mijović L, Mikenberg G, Mikestikova M, Mikuž M, Miller DW, Miller RJ, Mills WJ, Mills C, Milov A, Milstead DA, Milstein D, Minaenko AA, Miñano M, Minashvili IA, Mincer AI, Mindur B, Mineev M, Ming Y, Mir LM, Mirabelli G, Miralles Verge L, Misiejuk A, Mitrevski J, Mitrofanov GY, Mitsou VA, Mitsui S, Miyagawa PS, Miyazaki K, Mjörnmark JU, Moa T, Mockett P, Moed S, Moeller V, Mönig K, Möser N, Mohapatra S, Mohr W, Mohrdieck-Möck S, Moisseev AM, Moles-Valls R, Molina-Perez J, Monk J, Monnier E, Montesano S, Monticelli F, Monzani S, Moore RW, Moorhead GF, Mora Herrera C, Moraes A, Morange N, Morel J, Morello G, Moreno D, Moreno Llácer M, Morettini P, Morii M, Morin J, Morley AK, Mornacchi G, Morozov SV, Morris JD, Morvaj L, Moser HG, Mosidze M, Moss J, Mount R, Mountricha E, Mouraviev SV, Moyse EJW, Mudrinic M, Mueller F, Mueller J, Mueller K, Müller TA, Muenstermann D, Muir A, Munwes Y, Murray WJ, Mussche I, Musto E, Myagkov AG, Myska M, Nadal J, Nagai K, Nagano K, Nagasaka Y, Nairz AM, Nakahama Y, Nakamura K, Nakamura T, Nakano I, Nanava G, Napier A, Nash M, Nation NR, Nattermann T, Naumann T, Navarro G, Neal HA, Nebot E, Nechaeva PY, Negri A, Negri G, Nektarijevic S, Nelson A, Nelson S, Nelson TK, Nemecek S, Nemethy P, Nepomuceno AA, Nessi M, Neubauer MS, Neusiedl A, Neves RM, Nevski P, Newman PR, Nguyen Thi Hong V, Nickerson RB, Nicolaidou R, Nicolas L, Nicquevert B, Niedercorn F, Nielsen J, Niinikoski T, Nikiforou N, Nikiforov A, Nikolaenko V, Nikolaev K, Nikolic-Audit I, Nikolics K, Nikolopoulos K, Nilsen H, Nilsson P, Ninomiya Y, Nisati A, Nishiyama T, Nisius R, Nodulman L, Nomachi M, Nomidis I, Nordberg M, Nordkvist B, Norton PR, Novakova J, Nozaki M, Nozka L, Nugent IM, Nuncio-Quiroz AE, Nunes Hanninger G, Nunnemann T, Nurse E, Nyman T, O'Brien BJ, O'Neale SW, O'Neil DC, O'Shea V, Oakham FG, Oberlack H, Ocariz J, Ochi A, Oda S, Odaka S, Odier J, Ogren H, Oh A, Oh SH, Ohm CC, Ohshima T, Ohshita H, Ohsugi T, Okada S, Okawa H, Okumura Y, Okuyama T, Olariu A, Olcese M, Olchevski AG, Oliveira M, Oliveira Damazio D, Oliver Garcia E, Olivito D, Olszewski A, Olszowska J, Omachi C, Onofre A, Onyisi PUE, Oram CJ, Oreglia MJ, Oren Y, Orestano D, Orlov I, Oropeza Barrera C, Orr RS, Osculati B, Ospanov R, Osuna C, Otero Y Garzon G, Ottersbach JP, Ouchrif M, Ould-Saada F, Ouraou A, Ouyang Q, Owen M, Owen S, Ozcan VE, Ozturk N, Pacheco Pages A, Padilla Aranda C, Pagan Griso S, Paganis E, Paige F, Pais P, Pajchel K, Palacino G, Paleari CP, Palestini S, Pallin D, Palma A, Palmer JD, Pan YB, Panagiotopoulou E, Panes B, Panikashvili N, Panitkin S, Pantea D, Panuskova M, Paolone V, Papadelis A, Papadopoulou TD, Paramonov A, Park W, Parker MA, Parodi F, Parsons JA, Parzefall U, Pasqualucci E, Passeri A, Pastore F, Pastore F, Pásztor G, Pataraia S, Patel N, Pater JR, Patricelli S, Pauly T, Pecsy M, Pedraza Morales MI, Peleganchuk SV, Peng H, Pengo R, Penson A, Penwell J, Perantoni M, Perez K, Perez Cavalcanti T, Perez Codina E, Pérez García-Estañ MT, Perez Reale V, Perini L, Pernegger H, Perrino R, Perrodo P, Persembe S, Peshekhonov VD, Petersen BA, Petersen J, Petersen TC, Petit E, Petridis A, Petridou C, Petrolo E, Petrucci F, Petschull D, Petteni M, Pezoa R, Phan A, Phillips AW, Phillips PW, Piacquadio G, Piccaro E, Piccinini M, Piec SM, Piegaia R, Pilcher JE, Pilkington AD, Pina J, Pinamonti M, Pinder A, Pinfold JL, Ping J, Pinto B, Pirotte O, Pizio C, Placakyte R, Plamondon M, Pleier MA, Pleskach AV, Poblaguev A, Poddar S, Podlyski F, Poggioli L, Poghosyan T, Pohl M, Polci F, Polesello G, Policicchio A, Polini A, Poll J, Polychronakos V, Pomarede DM, Pomeroy D, Pommès K, Pontecorvo L, Pope BG, Popeneciu GA, Popovic DS, Poppleton A, Portell Bueso X, Posch C, Pospelov GE, Pospisil S, Potrap IN, Potter CJ, Potter CT, Poulard G, Poveda J, Prabhu R, Pralavorio P, Prasad S, Pravahan R, Prell S, Pretzl K, Pribyl L, Price D, Price LE, Price MJ, Prieur D, Primavera M, Prokofiev K, Prokoshin F, Protopopescu S, Proudfoot J, Prudent X, Przysiezniak H, Psoroulas S, Ptacek E, Pueschel E, Purdham J, Purohit M, Puzo P, Pylypchenko Y, Qian J, Qian Z, Qin Z, Quadt A, Quarrie DR, Quayle WB, Quinonez F, Raas M, Radescu V, Radics B, Rador T, Ragusa F, Rahal G, Rahimi AM, Rahm D, Rajagopalan S, Rammensee M, Rammes M, Ramstedt M, Randle-Conde AS, Randrianarivony K, Ratoff PN, Rauscher F, Raymond M, Read AL, Rebuzzi DM, Redelbach A, Redlinger G, Reece R, Reeves K, Reichold A, Reinherz-Aronis E, Reinsch A, Reisinger I, Reljic D, Rembser C, Ren ZL, Renaud A, Renkel P, Rescigno M, Resconi S, Resende B, Reznicek P, Rezvani R, Richards A, Richter R, Richter-Was E, Ridel M, Rijpstra M, Rijssenbeek M, Rimoldi A, Rinaldi L, Rios RR, Riu I, Rivoltella G, Rizatdinova F, Rizvi E, Robertson SH, Robichaud-Veronneau A, Robinson D, Robinson JEM, Robinson M, Robson A, Rocha de Lima JG, Roda C, Roda Dos Santos D, Rodier S, Rodriguez D, Roe A, Roe S, Røhne O, Rojo V, Rolli S, Romaniouk A, Romano M, Romanov VM, Romeo G, Roos L, Ros E, Rosati S, Rosbach K, Rose A, Rose M, Rosenbaum GA, Rosenberg EI, Rosendahl PL, Rosenthal O, Rosselet L, Rossetti V, Rossi E, Rossi LP, Rotaru M, Roth I, Rothberg J, Rousseau D, Royon CR, Rozanov A, Rozen Y, Ruan X, Rubinskiy I, Ruckert B, Ruckstuhl N, Rud VI, Rudolph C, Rudolph G, Rühr F, Ruggieri F, Ruiz-Martinez A, Rumiantsev V, Rumyantsev L, Runge K, Runolfsson O, Rurikova Z, Rusakovich NA, Rust DR, Rutherfoord JP, Ruwiedel C, Ruzicka P, Ryabov YF, Ryadovikov V, Ryan P, Rybar M, Rybkin G, Ryder NC, Rzaeva S, Saavedra AF, Sadeh I, Sadrozinski HFW, Sadykov R, Safai Tehrani F, Sakamoto H, Salamanna G, Salamon A, Saleem M, Salihagic D, Salnikov A, Salt J, Salvachua Ferrando BM, Salvatore D, Salvatore F, Salvucci A, Salzburger A, Sampsonidis D, Samset BH, Sanchez A, Sandaker H, Sander HG, Sanders MP, Sandhoff M, Sandoval T, Sandoval C, Sandstroem R, Sandvoss S, Sankey DPC, Sansoni A, Santamarina Rios C, Santoni C, Santonico R, Santos H, Saraiva JG, Sarangi T, Sarkisyan-Grinbaum E, Sarri F, Sartisohn G, Sasaki O, Sasaki T, Sasao N, Satsounkevitch I, Sauvage G, Sauvan E, Sauvan JB, Savard P, Savinov V, Savu DO, Sawyer L, Saxon DH, Says LP, Sbarra C, Sbrizzi A, Scallon O, Scannicchio DA, Schaarschmidt J, Schacht P, Schäfer U, Schaepe S, Schaetzel S, Schaffer AC, Schaile D, Schamberger RD, Schamov AG, Scharf V, Schegelsky VA, Scheirich D, Schernau M, Scherzer MI, Schiavi C, Schieck J, Schioppa M, Schlenker S, Schlereth JL, Schmidt E, Schmieden K, Schmitt C, Schmitt S, Schmitz M, Schöning A, Schott M, Schouten D, Schovancova J, Schram M, Schroeder C, Schroer N, Schuh S, Schuler G, Schultes J, Schultz-Coulon HC, Schulz H, Schumacher JW, Schumacher M, Schumm BA, Schune P, Schwanenberger C, Schwartzman A, Schwemling P, Schwienhorst R, Schwierz R, Schwindling J, Schwindt T, Scott WG, Searcy J, Sedov G, Sedykh E, Segura E, Seidel SC, Seiden A, Seifert F, Seixas JM, Sekhniaidze G, Seliverstov DM, Sellden B, Sellers G, Seman M, Semprini-Cesari N, Serfon C, Serin L, Seuster R, Severini H, Sevior ME, Sfyrla A, Shabalina E, Shamim M, Shan LY, Shank JT, Shao QT, Shapiro M, Shatalov PB, Shaver L, Shaw K, Sherman D, Sherwood P, Shibata A, Shichi H, Shimizu S, Shimojima M, Shin T, Shiyakova M, Shmeleva A, Shochet MJ, Short D, Shupe MA, Sicho P, Sidoti A, Siebel A, Siegert F, Sijacki D, Silbert O, Silva J, Silver Y, Silverstein D, Silverstein SB, Simak V, Simard O, Simic L, Simion S, Simmons B, Simonyan M, Sinervo P, Sinev NB, Sipica V, Siragusa G, Sircar A, Sisakyan AN, Sivoklokov SY, Sjölin J, Sjursen TB, Skinnari LA, Skottowe HP, Skovpen K, Skubic P, Skvorodnev N, Slater M, Slavicek T, Sliwa K, Sloper J, Smakhtin V, Smirnov SY, Smirnova LN, Smirnova O, Smith BC, Smith D, Smith KM, Smizanska M, Smolek K, Snesarev AA, Snow SW, Snow J, Snuverink J, Snyder S, Soares M, Sobie R, Sodomka J, Soffer A, Solans CA, Solar M, Solc J, Soldatov E, Soldevila U, Solfaroli Camillocci E, Solodkov AA, Solovyanov OV, Sondericker J, Soni N, Sopko V, Sopko B, Sosebee M, Soualah R, Soukharev A, Spagnolo S, Spanò F, Spighi R, Spigo G, Spila F, Spiwoks R, Spousta M, Spreitzer T, Spurlock B, St Denis RD, Stahl T, Stahlman J, Stamen R, Stanecka E, Stanek RW, Stanescu C, Stapnes S, Starchenko EA, Stark J, Staroba P, Starovoitov P, Staude A, Stavina P, Stavropoulos G, Steele G, Steinbach P, Steinberg P, Stekl I, Stelzer B, Stelzer HJ, Stelzer-Chilton O, Stenzel H, Stevenson K, Stewart GA, Stillings JA, Stockton MC, Stoerig K, Stoicea G, Stonjek S, Strachota P, Stradling AR, Straessner A, Strandberg J, Strandberg S, Strandlie A, Strang M, Strauss E, Strauss M, Strizenec P, Ströhmer R, Strom DM, Strong JA, Stroynowski R, Strube J, Stugu B, Stumer I, Stupak J, Sturm P, Soh DA, Su D, Subramania H, Succurro A, Sugaya Y, Sugimoto T, Suhr C, Suita K, Suk M, Sulin VV, Sultansoy S, Sumida T, Sun X, Sundermann JE, Suruliz K, Sushkov S, Susinno G, Sutton MR, Suzuki Y, Suzuki Y, Svatos M, Sviridov YM, Swedish S, Sykora I, Sykora T, Szeless B, Sánchez J, Ta D, Tackmann K, Taffard A, Tafirout R, Taiblum N, Takahashi Y, Takai H, Takashima R, Takeda H, Takeshita T, Talby M, Talyshev A, Tamsett MC, Tanaka J, Tanaka R, Tanaka S, Tanaka S, Tanaka Y, Tani K, Tannoury N, Tappern GP, Tapprogge S, Tardif D, Tarem S, Tarrade F, Tartarelli GF, Tas P, Tasevsky M, Tassi E, Tatarkhanov M, Tayalati Y, Taylor C, Taylor FE, Taylor GN, Taylor W, Teinturier M, Teixeira Dias Castanheira M, Teixeira-Dias P, Temming KK, Ten Kate H, Teng PK, Terada S, Terashi K, Terron J, Terwort M, Testa M, Teuscher RJ, Thadome J, Therhaag J, Theveneaux-Pelzer T, Thioye M, Thoma S, Thomas JP, Thompson EN, Thompson PD, Thompson PD, Thompson AS, Thomson E, Thomson M, Thun RP, Tian F, Tic T, Tikhomirov VO, Tikhonov YA, Tipton P, Tique Aires Viegas FJ, Tisserant S, Tobias J, Toczek B, Todorov T, Todorova-Nova S, Toggerson B, Tojo J, Tokár S, Tokunaga K, Tokushuku K, Tollefson K, Tomoto M, Tompkins L, Toms K, Tong G, Tonoyan A, Topfel C, Topilin ND, Torchiani I, Torrence E, Torres H, Torró Pastor E, Toth J, Touchard F, Tovey DR, Traynor D, Trefzger T, Tremblet L, Tricoli A, Trigger IM, Trincaz-Duvoid S, Trinh TN, Tripiana MF, Trischuk W, Trivedi A, Trocmé B, Troncon C, Trottier-McDonald M, Trzebinski M, Trzupek A, Tsarouchas C, Tseng JCL, Tsiakiris M, Tsiareshka PV, Tsionou D, Tsipolitis G, Tsiskaridze V, Tskhadadze EG, Tsukerman II, Tsulaia V, Tsung JW, Tsuno S, Tsybychev D, Tua A, Tudorache A, Tudorache V, Tuggle JM, Turala M, Turecek D, Turk Cakir I, Turlay E, Turra R, Tuts PM, Tykhonov A, Tylmad M, Tyndel M, Tyrvainen H, Tzanakos G, Uchida K, Ueda I, Ueno R, Ugland M, Uhlenbrock M, Uhrmacher M, Ukegawa F, Unal G, Underwood DG, Undrus A, Unel G, Unno Y, Urbaniec D, Urkovsky E, Usai G, Uslenghi M, Vacavant L, Vacek V, Vachon B, Vahsen S, Valenta J, Valente P, Valentinetti S, Valkar S, Valladolid Gallego E, Vallecorsa S, Valls Ferrer JA, van der Graaf H, van der Kraaij E, Van Der Leeuw R, van der Poel E, van der Ster D, van Eldik N, van Gemmeren P, van Kesteren Z, van Vulpen I, Vanadia M, Vandelli W, Vandoni G, Vaniachine A, Vankov P, Vannucci F, Varela Rodriguez F, Vari R, Varouchas D, Vartapetian A, Varvell KE, Vassilakopoulos VI, Vazeille F, Vegni G, Veillet JJ, Vellidis C, Veloso F, Veness R, Veneziano S, Ventura A, Ventura D, Venturi M, Venturi N, Vercesi V, Verducci M, Verkerke W, Vermeulen JC, Vest A, Vetterli MC, Vichou I, Vickey T, Vickey Boeriu OE, Viehhauser GHA, Viel S, Villa M, Villaplana Perez M, Vilucchi E, Vincter MG, Vinek E, Vinogradov VB, Virchaux M, Virzi J, Vitells O, Viti M, Vivarelli I, Vives Vaque F, Vlachos S, Vladoiu D, Vlasak M, Vlasov N, Vogel A, Vokac P, Volpi G, Volpi M, Volpini G, von der Schmitt H, von Loeben J, von Radziewski H, von Toerne E, Vorobel V, Vorobiev AP, Vorwerk V, Vos M, Voss R, Voss TT, Vossebeld JH, Vranjes N, Vranjes Milosavljevic M, Vrba V, Vreeswijk M, Vu Anh T, Vuillermet R, Vukotic I, Wagner W, Wagner P, Wahlen H, Wakabayashi J, Walbersloh J, Walch S, Walder J, Walker R, Walkowiak W, Wall R, Waller P, Wang C, Wang H, Wang H, Wang J, Wang J, Wang JC, Wang R, Wang SM, Warburton A, Ward CP, Warsinsky M, Watkins PM, Watson AT, Watson MF, Watts G, Watts S, Waugh AT, Waugh BM, Weber J, Weber M, Weber MS, Weber P, Weidberg AR, Weigell P, Weingarten J, Weiser C, Wellenstein H, Wells PS, Wen M, Wenaus T, Wendler S, Weng Z, Wengler T, Wenig S, Wermes N, Werner M, Werner P, Werth M, Wessels M, Weydert C, Whalen K, Wheeler-Ellis SJ, Whitaker SP, White A, White MJ, Whitehead SR, Whiteson D, Whittington D, Wicke D, Wickens FJ, Wiedenmann W, Wielers M, Wienemann P, Wiglesworth C, Wiik LAM, Wijeratne PA, Wildauer A, Wildt MA, Wilhelm I, Wilkens HG, Will JZ, Williams E, Williams HH, Willis W, Willocq S, Wilson JA, Wilson MG, Wilson A, Wingerter-Seez I, Winkelmann S, Winklmeier F, Wittgen M, Wolter MW, Wolters H, Wong WC, Wooden G, Wosiek BK, Wotschack J, Woudstra MJ, Wraight K, Wright C, Wright M, Wrona B, Wu SL, Wu X, Wu Y, Wulf E, Wunstorf R, Wynne BM, Xella S, Xiao M, Xie S, Xie Y, Xu C, Xu D, Xu G, Yabsley B, Yacoob S, Yamada M, Yamaguchi H, Yamamoto A, Yamamoto K, Yamamoto S, Yamamura T, Yamanaka T, Yamaoka J, Yamazaki T, Yamazaki Y, Yan Z, Yang H, Yang UK, Yang Y, Yang Y, Yang Z, Yanush S, Yasu Y, Ybeles Smit GV, Ye J, Ye S, Yilmaz M, Yoosoofmiya R, Yorita K, Yoshida R, Young C, Youssef S, Yu D, Yu J, Yu J, Yuan L, Yurkewicz A, Zaets VG, Zaidan R, Zaitsev AM, Zajacova Z, Zalite YK, Zanello L, Zarzhitsky P, Zaytsev A, Zeitnitz C, Zeller M, Zeman M, Zemla A, Zendler C, Zenin O, Zeniš T, Zenonos Z, Zenz S, Zerwas D, Zevi Della Porta G, Zhan Z, Zhang D, Zhang H, Zhang J, Zhang X, Zhang Z, Zhao L, Zhao T, Zhao Z, Zhemchugov A, Zheng S, Zhong J, Zhou B, Zhou N, Zhou Y, Zhu CG, Zhu H, Zhu J, Zhu Y, Zhuang X, Zhuravlov V, Zieminska D, Zimmermann R, Zimmermann S, Zimmermann S, Ziolkowski M, Zitoun R, Zivković L, Zmouchko VV, Zobernig G, Zoccoli A, Zolnierowski Y, Zsenei A, Zur Nedden M, Zutshi V, Zwalinski L. Measurement of the ZZ production cross section and limits on anomalous neutral triple gauge couplings in proton-proton collisions at sqrt[s] = 7 TeV with the ATLAS detector. Phys Rev Lett 2012; 108:041804. [PMID: 22400826 DOI: 10.1103/physrevlett.108.041804] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/23/2011] [Indexed: 05/31/2023]
Abstract
A measurement of the ZZ production cross section in proton-proton collisions at sqrt[s] = 7 TeV using data corresponding to an integrated luminosity of 1.02 fb(-1) recorded by the ATLAS experiment at the LHC is presented. Twelve events containing two Z boson candidates decaying to electrons and/or muons are observed, with an expected background of 0.3 ± 0.3(stat)(-0.3)(+0.4)(syst) events. The cross section measured in a phase-space region with good detector acceptance and for dilepton masses within the range 66 to 116 GeV is σ(ZZ → ℓ+ ℓ- ℓ+ ℓ-)(fid) = 19.4(-5.2)(+6.3)(stat)(-0.7)(+0.9)(syst) ± 0.7(lumi) fb. The resulting total cross section for on-shell ZZ production, σ(ZZ)(tot) = 8.5(-2.3)(+2.7)(stat)(-0.3)(+0.4)(syst) ± 0.3(lumi) pb, is consistent with the standard model expectation of 6.5(-0.2)(+0.3) pb calculated at the next-to-leading order in QCD. Limits on anomalous neutral triple gauge boson couplings are derived.
Collapse
Affiliation(s)
- G Aad
- Fakultät für Mathematik und Physik, Albert-Ludwigs-Universität, Freiburg i.Br., Germany
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Vaidya JS, Baum M, Wenz F, Bulsara M, Tobias J, Alvarodo M, Saunders C, Williams N, Joseph D. P3-13-07: The TARGIT-A Trial Update Confirms No Increase in Local Recurrence. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p3-13-07] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: In June 2010, we published the results of the TARGIT-A trial (1) that compared “one-size fits” all radiotherapy (whole breast radiotherapy-EBRT group) with risk -adjusted radiotherapy (TARGIT- group: single dose TARGeted Intraoperative radioTherapy with additional whole breast radiotherapy if adverse prognostic factors were found). These results showed that the risk of local recurrence in the TARGIT group was non-inferior to that of the EBRT group (the difference between the two arms was 0.25% at 4 years). We now report the results analyzed after further follow up of the total trial cohort without unblinding.
Method: As often repeated, unplanned analysis comparing two groups in a randomized trial can result in an increased alpha-spent as well as carry the risk of a false positive result, we have remained blinded to the further recurrences in the trial according to allocated treatment, since the original publication in the Lancet. Instead we proposed and performed a blinded analysis of the local recurrence rate for the whole cohort. We plotted the Kaplan Meier plots and compared the estimated 4-year recurrences.
Results: Amongst the 2232 patients randomized, there were 13 recurrences at the time of Lancet publication and since then, we have had 8 additional recurrences. The number of patients who have completed at least 4 years of follow up has increased from 420 to 717. We found that the 4-year Kaplan Meier estimate of local recurrence was 1.08% (95% CI 0.59 −1.96) at the time of the Lancet publication and it is 1.09% (95% CI 0.65 - 1.85) now.
Conclusion: We found that the overall 4-year recurrence rates of the TARGIT-A trial have remained stable with a longer follow up and therefore; it is statistically implausible, that one particular arm has a significantly higher local recurrence.
References
1. Vaidya JS, Joseph DJ, Tobias JS, Bulsara M, Wenz F, Saunders C, Alvarado M, Flyger HL, Massarut S, Eiermann W, Keshtgar M, Dewar J, Kraus-Tiefenbacher U, Sutterlin M, Esserman L, Holtveg HM, Roncadin M, Pigorsch S, Metaxas M, Falzon M, Matthews A, Corica T, Williams NR, Baum M. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet 2010;376(9735):91–102.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P3-13-07.
Collapse
Affiliation(s)
- JS Vaidya
- 1University College London, London, United Kingdom; University of Heidelberg, Mannheim, United Kingdom; University of Notre Dame, Fremantle, United Kingdom; University College Hospital and Whittington Hospital, London, United Kingdom; School of Surgery, University of Western Australia, London (All), United Kingdom; University of San Francisco, London (All), United Kingdom; Sir Charles Gairdener Hospital, London (All), United Kingdom
| | - M Baum
- 1University College London, London, United Kingdom; University of Heidelberg, Mannheim, United Kingdom; University of Notre Dame, Fremantle, United Kingdom; University College Hospital and Whittington Hospital, London, United Kingdom; School of Surgery, University of Western Australia, London (All), United Kingdom; University of San Francisco, London (All), United Kingdom; Sir Charles Gairdener Hospital, London (All), United Kingdom
| | - F Wenz
- 1University College London, London, United Kingdom; University of Heidelberg, Mannheim, United Kingdom; University of Notre Dame, Fremantle, United Kingdom; University College Hospital and Whittington Hospital, London, United Kingdom; School of Surgery, University of Western Australia, London (All), United Kingdom; University of San Francisco, London (All), United Kingdom; Sir Charles Gairdener Hospital, London (All), United Kingdom
| | - M Bulsara
- 1University College London, London, United Kingdom; University of Heidelberg, Mannheim, United Kingdom; University of Notre Dame, Fremantle, United Kingdom; University College Hospital and Whittington Hospital, London, United Kingdom; School of Surgery, University of Western Australia, London (All), United Kingdom; University of San Francisco, London (All), United Kingdom; Sir Charles Gairdener Hospital, London (All), United Kingdom
| | - J Tobias
- 1University College London, London, United Kingdom; University of Heidelberg, Mannheim, United Kingdom; University of Notre Dame, Fremantle, United Kingdom; University College Hospital and Whittington Hospital, London, United Kingdom; School of Surgery, University of Western Australia, London (All), United Kingdom; University of San Francisco, London (All), United Kingdom; Sir Charles Gairdener Hospital, London (All), United Kingdom
| | - M Alvarodo
- 1University College London, London, United Kingdom; University of Heidelberg, Mannheim, United Kingdom; University of Notre Dame, Fremantle, United Kingdom; University College Hospital and Whittington Hospital, London, United Kingdom; School of Surgery, University of Western Australia, London (All), United Kingdom; University of San Francisco, London (All), United Kingdom; Sir Charles Gairdener Hospital, London (All), United Kingdom
| | - C Saunders
- 1University College London, London, United Kingdom; University of Heidelberg, Mannheim, United Kingdom; University of Notre Dame, Fremantle, United Kingdom; University College Hospital and Whittington Hospital, London, United Kingdom; School of Surgery, University of Western Australia, London (All), United Kingdom; University of San Francisco, London (All), United Kingdom; Sir Charles Gairdener Hospital, London (All), United Kingdom
| | - N Williams
- 1University College London, London, United Kingdom; University of Heidelberg, Mannheim, United Kingdom; University of Notre Dame, Fremantle, United Kingdom; University College Hospital and Whittington Hospital, London, United Kingdom; School of Surgery, University of Western Australia, London (All), United Kingdom; University of San Francisco, London (All), United Kingdom; Sir Charles Gairdener Hospital, London (All), United Kingdom
| | - D Joseph
- 1University College London, London, United Kingdom; University of Heidelberg, Mannheim, United Kingdom; University of Notre Dame, Fremantle, United Kingdom; University College Hospital and Whittington Hospital, London, United Kingdom; School of Surgery, University of Western Australia, London (All), United Kingdom; University of San Francisco, London (All), United Kingdom; Sir Charles Gairdener Hospital, London (All), United Kingdom
| | | |
Collapse
|
25
|
Vagadia V, Bartholomew P, Kelly M, Handley G, Kelly C, Bridges M, Ruddick S, Malik R, Gilleece Y, Fisher M, Walker-Bone K, Selvan S, Collins DA, Meryon I, Pattle J, Scurr C, Davies G, Callan M, Mercieca C, Down M, Webb J, Shipley J, Bhalla AK, Poole KE, Treece GM, Ridgway GR, Mayhew PM, Borggrefe J, Gee AH, Mehta P, Nelson M, Boag F, Oldroyd AG, Halsey J, Goodson NJ, Greenbank C, Evans B, Bukhari M, Azagra R, Roca G, Encabo G, Aguye A, Zwart M, Casado E, Iglesias M, Puchol N, Sola S, Guell S, Harvey NC, Garrett E, Sheppard A, McLean C, Lillycrop K, Burdge G, Slater-Jefferies J, Rodford J, Crozier S, Inskip H, Starling Emerald B, Gale C, Hanson M, Gluckman P, Godfrey K, Cooper C, Edwards MH, Jameson K, Denison H, Aihie Sayer A, Cooper C, Dennison E, Cole Z, Harvey NC, Kim M, Robinson S, Inskip H, Godfrey KM, Cooper C, Dennison E, Clark EM, Morrison L, Gould V, Cuming M, Tobias J. Osteoporosis and metabolic bone disease: 73. Do Low Vitamin D Levels Predict Osteoporosis? Rheumatology (Oxford) 2011. [DOI: 10.1093/rheumatology/ker042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
26
|
Clark E, Tobias J, Fraser B. What's new in metabolic bone disease?: IP73. Is Frax Useful for Identifying People with Vertebral Fracture? Rheumatology (Oxford) 2011. [DOI: 10.1093/rheumatology/ker081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
27
|
Clark E, Tobias J. Educational achievement and fracture risk. Osteoporos Int 2010; 21:1625; author reply 1623. [PMID: 20012019 DOI: 10.1007/s00198-009-1115-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/10/2009] [Accepted: 09/29/2009] [Indexed: 11/30/2022]
|
28
|
Gillmore R, Laurence V, Raouf S, Tobias J, Blackman G, Meyer T, Goodchild K, Collis C, Bridgewater J. Chemoradiotherapy with or without induction chemotherapy for locally advanced pancreatic cancer: a UK multi-institutional experience. Clin Oncol (R Coll Radiol) 2010; 22:564-9. [PMID: 20605709 DOI: 10.1016/j.clon.2010.05.007] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2009] [Revised: 03/16/2010] [Accepted: 05/05/2010] [Indexed: 01/19/2023]
Abstract
AIMS The optimal management for patients with unresectable locally advanced adenocarcinoma of the pancreas (LAPC) is unclear. The aim of this study was to determine the outcome of patients treated with chemoradiotherapy (CRT) with or without induction chemotherapy. MATERIALS AND METHODS We conducted a multi-centre retrospective analysis of 48 patients with biopsy-proven LAPC treated with CRT in four regional oncology centres in the UK between March 2000 and October 2007. The prescribed radiotherapy dose was 4500-5040 cGy in 25-28 fractions and was given concurrent with gemcitabine (n=37), gemcitabine/cisplatin (n=9), 5-fluorouracil (n=1) or capecitabine (n=1). RESULTS Four patients (8.3%) did not complete the intended treatment due to CRT-related toxicities. The disease control rate (Objective response rate (ORR) and stable disease (SD)) was 81.3%. The median overall survival was 17 months (range 5-66 months). In subgroup analysis, a trend towards improved survival was seen in patients who completed the intended treatment (17.1 months vs 11.0 months, P=0.06) and in patients undergoing surgery (27 months vs 16 months, P=0.023). CONCLUSIONS This is the largest reported series from the UK focussing on patients who received CRT for pancreas cancer. It shows that it is possible to deliver pancreatic CRT with acceptable toxicity. Induction chemotherapy followed by gemcitabine-based CRT shows promising activity and should be evaluated in phase III studies.
Collapse
Affiliation(s)
- R Gillmore
- University College Hospital, University College London Cancer Institute, London, UK
| | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Keshtgar M, Vaidya J, Stacey C, Tobias J, Williams N, Baum M. Single dose radiotherapy during surgery for breast cancer patients where external beam radiation was not feasible - results after 3 years of follow-up. Eur J Surg Oncol 2009. [DOI: 10.1016/j.ejso.2009.07.145] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
30
|
Baum M, Williams N, Vaidya J, Keshtgar M, Tobias J. TARGIT: an international trial of intraoperative versus external beam radiotherapy. Breast Cancer Res 2008. [PMCID: PMC3300776 DOI: 10.1186/bcr1957] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
31
|
Ebinuma H, Nakamoto N, Li Y, Price DA, Gostick E, Levine BL, Tobias J, Kwok WW, Chang KM. Identification and in vitro expansion of functional antigen-specific CD25+ FoxP3+ regulatory T cells in hepatitis C virus infection. J Virol 2008; 82:5043-53. [PMID: 18337568 PMCID: PMC2346728 DOI: 10.1128/jvi.01548-07] [Citation(s) in RCA: 135] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2007] [Accepted: 03/04/2008] [Indexed: 01/14/2023] Open
Abstract
CD4(+)CD25(+) regulatory T cells (CD25(+) Tregs) play a key role in immune regulation. Since hepatitis C virus (HCV) persists with increased circulating CD4(+)CD25(+) T cells and virus-specific effector T-cell dysfunction, we asked if CD4(+)CD25(+) T cells in HCV-infected individuals are similar to natural Tregs in uninfected individuals and if they include HCV-specific Tregs using the specific Treg marker FoxP3 at the single-cell level. We report that HCV-infected patients display increased circulating FoxP3(+) Tregs that are phenotypically and functionally indistinguishable from FoxP3(+) Tregs in uninfected subjects. Furthermore, HCV-specific FoxP3(+) Tregs were detected in HCV-seropositive persons with antigen-specific expansion, major histocompatibility complex class II/peptide tetramer binding affinity, and preferential suppression of HCV-specific CD8 T cells. Transforming growth factor beta contributed to antigen-specific Treg expansion in vitro, suggesting that it may contribute to antigen-specific Treg expansion in vivo. Interestingly, FoxP3 expression was also detected in influenza virus-specific CD4 T cells. In conclusion, functionally active and virus-specific FoxP3(+) Tregs are induced in HCV infection, thus providing targeted immune regulation in vivo. Detection of FoxP3 expression in non-HCV-specific CD4 T cells suggests that immune regulation through antigen-specific Treg induction extends beyond HCV.
Collapse
Affiliation(s)
- Hirotoshi Ebinuma
- Philadelphia Veterans Affairs Medical Center, Philadelphia, PA 19104, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Yang S, Farias M, Kapfhamer D, Tobias J, Grant G, Abel T, Bućan M. Biochemical, molecular and behavioral phenotypes of Rab3A mutations in the mouse. Genes Brain Behav 2007; 6:77-96. [PMID: 16734774 PMCID: PMC2914309 DOI: 10.1111/j.1601-183x.2006.00235.x] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Ras-associated binding (Rab) protein 3A is a neuronal guanosine triphosphate (GTP)-binding protein that binds synaptic vesicles and regulates synaptic transmission. A mouse mutant, earlybird (Ebd), with a point mutation in the GTP-binding domain of Rab3A (D77G), exhibits anomalies in circadian behavior and homeostatic response to sleep loss. Here, we show that the D77G substitution in the Ebd allele causes reduced GTP and GDP binding, whereas GTPase activity remains intact, leading to reduced protein levels of both Rab3A and rabphilin3A. Expression profiling of the cortex and hippocampus of Ebd and Rab3a-deficient mice revealed subtle differences between wild-type and mutant mice. Although mice were backcrossed for three generations to a C57BL/6J background, the most robust changes at the transcriptional level between Rab3a(-/-) and Rab3a(+/+) mice were represented by genes from the 129/Sv-derived chromosomal region surrounding the Rab3a gene. These results showed that differences in genetic background have a stronger effect on gene expression than the mutations in the Rab3a gene. In behavioral tests, the Ebd/Ebd mice showed a more pronounced mutant phenotype than the null mice; Ebd/Ebd have reduced anxiety-like behavior in the elevated zero-maze test, reduced response to stress in the forced swim test and a deficit in cued fear conditioning (FC), whereas Rab3a(-/-) showed only a deficit in cued FC. Our data implicate Rab3A in learning and memory as well as in the regulation of emotion. A combination of forward and reverse genetics has provided multiple alleles of the Rab3a gene; our studies illustrate the power and complexities of the parallel analysis of these alleles at the biochemical, molecular and behavioral levels.
Collapse
Affiliation(s)
- S. Yang
- Department of Genetics, University of Pennsylvania, Philadelphia, PA
| | - M. Farias
- Department of Genetics, University of Pennsylvania, Philadelphia, PA
| | - D. Kapfhamer
- Department of Genetics, University of Pennsylvania, Philadelphia, PA
| | - J. Tobias
- Penn Center for Bioinformatics, University of Pennsylvania, Philadelphia, PA, USA
| | - G. Grant
- Department of Genetics, University of Pennsylvania, Philadelphia, PA
- Penn Center for Bioinformatics, University of Pennsylvania, Philadelphia, PA, USA
| | - T. Abel
- Department of Biology, University of Pennsylvania, Philadelphia, PA, USA
| | - M. Bućan
- Department of Genetics, University of Pennsylvania, Philadelphia, PA
- Penn Center for Bioinformatics, University of Pennsylvania, Philadelphia, PA, USA
| |
Collapse
|
33
|
Keshtgar M, Tobias J, Vaidya J, Murphy O, Stacey C, Metaxas M, Douek M, Sainsbury R, Houghton J, Baum M. 286 POSTER Use of intra-operative radiotherapy [IORT] alone in breast cancer patients when conventional external beam radiation therapy [EBRT] was not possible. Eur J Surg Oncol 2006. [DOI: 10.1016/s0748-7983(06)70721-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
|
34
|
Bourhis J, Le Maı̂tre A, Pignon J, Ang K, Bernier J, Overgaard J, Tobias J, Saunders M, Adelstein D, O’Sullivan B. Impact of age on treatment effect in locally advanced head and neck cancer (HNC): Two individual patient data meta-analyses. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.5501] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5501 Background: The Meta-Analysis of Radiotherapy in Carcinomas of Head & Neck (MARCH; Bourhis J, ASTRO 2002) showed that altered fractionation radiotherapy (Alt-RT) could improve survival as compared to standard RT in patients with locally advanced HNC (pooled hazard ratio - HR -: 0.92, 95% confidence interval: 0.86–0.97). The Meta-Analysis of Chemotherapy in Head and Neck Cancer (MACH-NC; Bourhis J, ASCO 2004) demonstrated that concomitant chemotherapy (CT), added to RT, improved survival (HR: 0.82, 95% CI: 0.78–0.86). This study considers age as a potential modifier of the treatment effect. Methods: 15 randomized trials with 6,515 patients were included in MARCH (median follow up: 6.0 years), and 50 with 9,471 patients in concomitant part of MACH-NC (median follow up: 5.6 years). The interaction between age and treatment effect, using HR of death, was tested with heterogeneity test. Effect of prognostic factors on the interaction was analysed using Cox model. Results: The effect of Alt-RT in MARCH and of concomitant CT in MACH-NC on overall survival decreased with increased age ( table ). Patients aged 71+ had a lower performance status, less advanced stage, and more often laryngeal cancer than the younger patients; there were more women in the oldest patients group. However, adjusting on covariates did not modify the results. Causes of death was available in MARCH and in recent (1994–2000) trials of MACH-NC. The proportion of deaths not due to HNC increased with age, from 18% at age 50 to 41% at age 71+ in MARCH, and from 15% to 39% in MACH-NC. Conclusions: Treatment benefit decreases with increasing age. Patients aged 71+ did not benefit from Alt- RT nor from concomitant CT. The increasing risk of death from other causes with age may explain part of these observations. Supported by PHRC, ARC, LNCC [Table: see text] No significant financial relationships to disclose.
Collapse
Affiliation(s)
- J. Bourhis
- Institut Gustave Roussy, Villejuif, France; Radiation Therapy Oncology Group, Philadelphia, PA; EORTC, Brussels, Belgium; Danish Head and Neck Cancer Group, Aarhus, Denmark; UKHAN, London, United Kingdom; Mount Vernon Hospital, Middlesex, United Kingdom; Eastern Cooperative Oncology Group, Boston, MA; Princess Margaret Hospital, Toronto, PQ, Canada
| | - A. Le Maı̂tre
- Institut Gustave Roussy, Villejuif, France; Radiation Therapy Oncology Group, Philadelphia, PA; EORTC, Brussels, Belgium; Danish Head and Neck Cancer Group, Aarhus, Denmark; UKHAN, London, United Kingdom; Mount Vernon Hospital, Middlesex, United Kingdom; Eastern Cooperative Oncology Group, Boston, MA; Princess Margaret Hospital, Toronto, PQ, Canada
| | - J. Pignon
- Institut Gustave Roussy, Villejuif, France; Radiation Therapy Oncology Group, Philadelphia, PA; EORTC, Brussels, Belgium; Danish Head and Neck Cancer Group, Aarhus, Denmark; UKHAN, London, United Kingdom; Mount Vernon Hospital, Middlesex, United Kingdom; Eastern Cooperative Oncology Group, Boston, MA; Princess Margaret Hospital, Toronto, PQ, Canada
| | - K. Ang
- Institut Gustave Roussy, Villejuif, France; Radiation Therapy Oncology Group, Philadelphia, PA; EORTC, Brussels, Belgium; Danish Head and Neck Cancer Group, Aarhus, Denmark; UKHAN, London, United Kingdom; Mount Vernon Hospital, Middlesex, United Kingdom; Eastern Cooperative Oncology Group, Boston, MA; Princess Margaret Hospital, Toronto, PQ, Canada
| | - J. Bernier
- Institut Gustave Roussy, Villejuif, France; Radiation Therapy Oncology Group, Philadelphia, PA; EORTC, Brussels, Belgium; Danish Head and Neck Cancer Group, Aarhus, Denmark; UKHAN, London, United Kingdom; Mount Vernon Hospital, Middlesex, United Kingdom; Eastern Cooperative Oncology Group, Boston, MA; Princess Margaret Hospital, Toronto, PQ, Canada
| | - J. Overgaard
- Institut Gustave Roussy, Villejuif, France; Radiation Therapy Oncology Group, Philadelphia, PA; EORTC, Brussels, Belgium; Danish Head and Neck Cancer Group, Aarhus, Denmark; UKHAN, London, United Kingdom; Mount Vernon Hospital, Middlesex, United Kingdom; Eastern Cooperative Oncology Group, Boston, MA; Princess Margaret Hospital, Toronto, PQ, Canada
| | - J. Tobias
- Institut Gustave Roussy, Villejuif, France; Radiation Therapy Oncology Group, Philadelphia, PA; EORTC, Brussels, Belgium; Danish Head and Neck Cancer Group, Aarhus, Denmark; UKHAN, London, United Kingdom; Mount Vernon Hospital, Middlesex, United Kingdom; Eastern Cooperative Oncology Group, Boston, MA; Princess Margaret Hospital, Toronto, PQ, Canada
| | - M. Saunders
- Institut Gustave Roussy, Villejuif, France; Radiation Therapy Oncology Group, Philadelphia, PA; EORTC, Brussels, Belgium; Danish Head and Neck Cancer Group, Aarhus, Denmark; UKHAN, London, United Kingdom; Mount Vernon Hospital, Middlesex, United Kingdom; Eastern Cooperative Oncology Group, Boston, MA; Princess Margaret Hospital, Toronto, PQ, Canada
| | - D. Adelstein
- Institut Gustave Roussy, Villejuif, France; Radiation Therapy Oncology Group, Philadelphia, PA; EORTC, Brussels, Belgium; Danish Head and Neck Cancer Group, Aarhus, Denmark; UKHAN, London, United Kingdom; Mount Vernon Hospital, Middlesex, United Kingdom; Eastern Cooperative Oncology Group, Boston, MA; Princess Margaret Hospital, Toronto, PQ, Canada
| | - B. O’Sullivan
- Institut Gustave Roussy, Villejuif, France; Radiation Therapy Oncology Group, Philadelphia, PA; EORTC, Brussels, Belgium; Danish Head and Neck Cancer Group, Aarhus, Denmark; UKHAN, London, United Kingdom; Mount Vernon Hospital, Middlesex, United Kingdom; Eastern Cooperative Oncology Group, Boston, MA; Princess Margaret Hospital, Toronto, PQ, Canada
| |
Collapse
|
35
|
Kirwan JR, Averns H, Creamer P, Davies M, Hickling P, Hutton C, Jacoby R, Kyle V, Laversuch C, Palferman T, Tobias J, Viner N, Woolf A, Yates D. Changes in rheumatology out-patient workload over 12 years in the South West of England. Rheumatology (Oxford) 2003; 42:175-9. [PMID: 12509633 DOI: 10.1093/rheumatology/keg056] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- J R Kirwan
- Academic Rheumatology, University Department of Medicine, Bristol Royal Infirmary, Bristol BS2 8HW, UK.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Abstract
STUDY DESIGN A prospective review of patients undergoing epidural catheter placement after anterior spinal fusion and instrumentation for adolescent scoliosis was performed. Data were collected using visual analog pain scores reflecting the patients' perception of their pain control. OBJECTIVES To present the authors' technique for epidural catheter placement and dosing protocol, and to demonstrate the results from postoperative pain control after anterior spinal instrumented fusion for 10 consecutive patients. SUMMARY OF BACKGROUND DATA The literature regarding the benefits of epidural catheters after spinal surgery is contradictory, even with controlled studies comparing epidural catheters with intravenous morphine patient-controlled anesthesia. The authors believe that this lack of consensus stems from varied epidural dosing protocols and techniques in catheter placement, which they have witnessed anecdotally at their own institution. This prompted the authors to develop and refine a standardized dosing and catheter placement protocol for pain control after spinal surgery. METHODS Epidural catheters were placed intraoperatively before wound closure, then removed on postoperative Day 5. Dosing consisted of fentanyl (1 microg/kg) and hydromorphone (5 microg/kg) diluted in preservative-free saline (0.2 mL/kg). After surgery, dosing consisted of 0.1% ropivacaine and hydromorphone (10 microg/ml) continuously infused at 0.2 mL/kg/hour. Postoperative pain control was assessed on each postoperative day using a visual analog pain scale with choices ranging from 0 to 10. RESULTS The arithmetic mean of the median pain scores after surgery was 2.1. The mean of the maximum pain scores for the 5 days was 4.1. Three patients required an epidural bolus and a 20% increase in the epidural infusion rate. One patient was judged to be excessively sleepy, so the epidural infusion rate was decreased by 20%. Pruritus requiring diphenhydramine developed in three patients. No other adverse effects related to epidural analgesia were noted. No catheters were accidentally pulled out or disconnected. CONCLUSION By following the dosing protocol described, epidural catheters can be used safely and effectively to control postoperative pain after anterior instrumentation and spinal fusion for adolescent scoliosis.
Collapse
Affiliation(s)
- K J Lowry
- Department of Orthopaedics Surgery, University of Missouri, Columbia, USA
| | | | | | | | | |
Collapse
|
37
|
Tobias J. The ATAC (Arimidex, Tamoxifen, alone or in combination) trial in post-menopausal patients with operable breast cancer. Eur J Cancer 2001. [DOI: 10.1016/s0959-8049(01)81116-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
38
|
Herod J, Burton A, Buxton J, Tobias J, Luesley D, Jordan S, Dunn J, Poole CJ. A randomised, prospective, phase III clinical trial of primary bleomycin, ifosfamide and cisplatin (BIP) chemotherapy followed by radiotherapy versus radiotherapy alone in inoperable cancer of the cervix. Ann Oncol 2000; 11:1175-81. [PMID: 11061615 DOI: 10.1023/a:1008346901733] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Phase II studies have shown primary (neo-adjuvant) chemotherapy with bleomycin, ifosfamide and cisplatin (BIP) is active against inoperable cervical cancer. We present here results of a randomised phase III multicentre trial comparing radical radiotherapy with neo-adjuvant BIP chemotherapy followed by radical radiotherapy in patients with inoperable cervical cancer, designed to discover whether this combination might improve survival. PATIENTS AND METHODS Patients with inoperable cervical carcinoma were randomised to pelvic radiotherapy alone [RT] or two to three cycles of bleomycin 30 units/24-hour infusion, ifosfamide 5 g/m2/24 hours, and cisplatin 50 mg/m2) chemotherapy followed by pelvic radiotherapy (BIP + RT). Randomisation was stratified by stage and radiotherapy centre. RESULTS One hundred seventy-two eligible women were randomised into this trial; eighty-six to RT and eighty-six to BIP + RT. A total of 190 cycles of chemotherapy were given. Median follow-up for the 47 patients still alive is 9 years with a minimum follow-up of 3 years. Complete or partial response occurred in 51 of 86 (59%) of those randomised to RT and 60 of 86 (69%) of those randomised to BIP + RT. The difference between response rates does not reach statistical significance (chi2 = 2.06, P = 0.15). Median survival is two years with an actuarial survival at five years of 32% (95% confidence interval (95% CI): 25%-39%). There is no significant difference between the treatment groups (chi2log-rank = 0.11, P = 0.74). CONCLUSIONS This study does not show any survival benefit from the use of neo-adjuvant BIP chemotherapy in advanced cervical cancer.
Collapse
Affiliation(s)
- J Herod
- CRC Trials Unit, Institute for Cancer Studies, University of Birmingham, Edgbaston, UK
| | | | | | | | | | | | | | | |
Collapse
|
39
|
Abstract
To investigate the relative importance of paternity defences in the European robin we used behavioural observations, simulated intrusions and temporary male removal experiments. Given that paired males did not increase their mate attendance, copulation rate or territory size during the female's fertile period, the most frequently quoted paternity assurance strategies in birds were absent. However, males with fertile females sang and patrolled their territories more regularly, suggesting that territorial motivation and vigilance were elevated when the risk of cuckoldry was greatest. In addition, there was a significant effect of breeding period on response to simulated intrusions: residents approached and attacked freeze-dried mounts more readily in the fertile period. During 90-min removals of the pair male in the fertile period, neighbours trespassed more frequently relative to prefertile and fertile period controls and appeared to seek copulations with unattended females. When replaced on their territories, males immediately increased both song rate and patrolling rate in comparison with controls. We propose that male robins sing to signal their presence, and increase their territorial vigilance and aggression in the fertile period to protect paternity. Copyright 2000 The Association for the Study of Animal Behaviour.
Collapse
Affiliation(s)
- J Tobias
- Department of Zoology, University of Cambridge
| | | |
Collapse
|
40
|
Cullen MH, Billingham LJ, Woodroffe CM, Chetiyawardana AD, Gower NH, Joshi R, Ferry DR, Rudd RM, Spiro SG, Cook JE, Trask C, Bessell E, Connolly CK, Tobias J, Souhami RL. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol 1999; 17:3188-94. [PMID: 10506617 DOI: 10.1200/jco.1999.17.10.3188] [Citation(s) in RCA: 369] [Impact Index Per Article: 14.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023] Open
Abstract
PURPOSE Chemotherapy for non-small-cell lung cancer (NSCLC) remains controversial. We describe the two largest reported, randomized, parallel trials designed to determine whether the addition of chemotherapy influences duration and quality of life in localized, unresectable (mitomycin, ifosfamide, cisplatin [MIC]1 trial) and extensive (MIC2 trial) disease. PATIENTS AND METHODS Ambulatory patients with NSCLC, aged 75 years or younger, with localized disease, were randomized in MIC1 to receive up to four cycles of chemotherapy (CT: mitomycin 6 mg/m(2), ifosfamide 3 g/m(2), and cisplatin 50 mg/m(2)) every 21 days, followed by radical radiotherapy (CT + RT) or radiotherapy (RT) alone. Extensive-stage patients were randomized in MIC2 to identical chemotherapy plus palliative care (CT + PC) or palliative care (PC) alone. Short-term change in quality of life (QOL) was assessed in a subgroup of patients. Data from the two trials were combined to allow multivariate and stratified survival analyses. RESULTS Seven hundred ninety-seven eligible patients were randomized, 446 in MIC1 and 351 in MIC2. MIC CT improved survival in both trials (significantly in MIC2). The median survival time in MIC1 was 11.7 months (CT + RT) versus 9.7 months (RT alone) (P =.14); whereas in MIC2, median survival time was 6.7 months (CT + PC) compared with 4. 8 months (PC alone) (P =.03). QOL, assessed in 134 patients from start of trial to week 6, showed improvement with chemotherapy and deterioration with standard treatment. In the combined analysis of 797 randomized patients, the positive effect of MIC on survival was significant overall (P =.01) and after adjusting for prognostic factors (P =.01). CONCLUSION MIC chemotherapy prolongs survival in unresectable NSCLC without compromising QOL.
Collapse
Affiliation(s)
- M H Cullen
- Queen Elizabeth Centre for the Treatment of Cancer, University Hospital Birmingham, Birmingham, United Kingdom.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Abstract
Estrogen replacement is currently the preferred therapy for postmenopausal osteoporosis, although its mechanism of action remains poorly understood. Its primary action on bone is generally considered to be antiresorptive, but there is evidence in animals to suggest a stimulatory effect on bone formation. We have now attempted to detect a similar effect in humans by administering hormone replacement therapy (estradiol valerate 2 mg/day and dydrogesterone 5 mg/day given in a continuous, combined manner) to ten postmenopausal women. We carried out histomorphometric analyses of transiliac bone biopsies after quadruple tetracycline labeling, which was commenced before and continued during the first 4 weeks of hormone replacement therapy. Biochemical markers of bone turnover suggested that bone resorption decreased, but no significant effects on histomorphometric parameters of bone formation were detected. We conclude that hormone replacement therapy at the dose given does not stimulate bone formation in the iliac crest as assessed by histomorphometry.
Collapse
Affiliation(s)
- S Patel
- Department of Rheumatology, St. Helier Hospital, Carshalton, Surrey, UK
| | | | | | | | | | | |
Collapse
|
42
|
Novak JS, Tobias J, Barkin JS. Nonsurgical management of acute jejunal diverticulitis: a review. Am J Gastroenterol 1997; 92:1929-31. [PMID: 9382070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
BACKGROUND Diverticular disease of the colon and its complications are well known and readily considered when patients present with the proper clinical scenario. Conversely, complications of small bowel diverticula are very uncommon entities and are not often thought of as a cause of bleeding, obstruction, or an acute abdomen. OBJECTIVE To report two patients presenting with an acute abdomen caused by acute jejunal diverticulitis who were treated nonsurgically as opposed to surgically as the literature dictates. METHODS Two patients presented with sudden onset of acute periumbilical pain that had increased progressively over 1-2 days before admission. An emergent CT scan performed in each patient with localized peritonitis revealed "collections" consistent with abscess cavities. One patient was treated with antibiotics alone and the other with a combination of antibiotics and percutaneous CT-guided aspiration. CT-guided needle aspiration was performed and the injection of contrast clearly revealed communication with a jejunal diverticulum. Both patients did well and were subsequently discharged without incident or surgical intervention. CONCLUSIONS Acute jejunal diverticulitis must be considered in the differential diagnosis of an acute abdominal process and may be successfully treated nonsurgically despite the recommendations of previous reports.
Collapse
Affiliation(s)
- J S Novak
- University of Miami, School of Medicine/Mt. Sinai Medical Center, Division of Gastroenterology, Florida, USA
| | | | | |
Collapse
|
43
|
Ninan M, Sommers KE, Landreneau RJ, Weyant RJ, Tobias J, Luketich JD, Ferson PF, Keenan RJ. Standardized exercise oximetry predicts postpneumonectomy outcome. Ann Thorac Surg 1997; 64:328-32; discussion 332-3. [PMID: 9262569 DOI: 10.1016/s0003-4975(97)00474-8] [Citation(s) in RCA: 65] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
BACKGROUND We have developed a safe, simple, and easily performed standardized exercise oximetry outpatient test to assess patients undergoing lung resections. We studied its ability to predict outcome after pneumonectomy in 46 consecutive patients over a 5-year period. METHODS Room air oximetry is initially performed at rest. The patient then begins to exercise on a stair-stepper apparatus (Stamina Stepper), which provides uniform resistance to stepping. Oxygen saturation values are noted at 10, 20, and 30 steps, equivalent to climbing three flights of stairs. Group 1 consisted of the patients who either had a resting saturation less than 90%, or desaturation greater than or equal to 4% during exercise. Group 2 consisted of all patients who had a preoperative forced expiratory volume in 1 second of 60% or less. Group 3 consisted of all patients who had a predicted postoperative forced expiratory volume in 1 second of 40% or less. Group 4 consisted of patients who had a predicted postoperative diffusing capacity of 40% or less. RESULTS There were four deaths (8.6%), 12 patients (26%) remained in the intensive care unit 4 or more days, and 11 patients (23%) suffered major morbidity. Desaturation during exercise (group 1) significantly predicted longer intensive care unit stay (p = 0.0002) and incidence of major morbidity (p < 0.0001). Groups 2, 3, and 4 were not significantly predictive of either longer intensive care unit stay or major morbidity. CONCLUSIONS Standardized exercise oximetry performed in the outpatient facility is highly predictive of major morbidity and prolonged intensive care unit stay after pneumonectomy.
Collapse
Affiliation(s)
- M Ninan
- Section of Thoracic Surgery, University of Pittsburgh Medical Center, Pennsylvania, USA
| | | | | | | | | | | | | | | |
Collapse
|
44
|
Abstract
A widespread feature of territorial systems is that residents almost invariably defeat challengers. This phenomenon has been explained by the existence of value asymmetries, variations in resource-holding potential or an 'owners always win' convention. Removal-replacement experiments were performed on 75 robins, Erithacus rubeculato test these hypotheses. The settling behaviour of newcomers was also examined in order to identify energetic costs incurred during territory establishment. In winter, dominance shifted gradually from removed owners to newcomers with increasing time of newcomer residence, and there was a peak in contest duration at 4-7 days. Removals of newcomers, followed by replacement with another newcomer, confirmed that dominance was determined by the time newcomers were in residence rather than the time original owners were absent. These results support the hypothesis that asymmetries in territory value govern the outcome of contests. It is proposed that high singing rates and low foraging rates of newcomers settling boundaries with neighbours contribute to this asymmetry, skewing outcomes in favour of original owners until replacements are fully established. The key result in this study is that the time at which dominance tends to reverse (5-6 days in winter) is predicted by the time taken for newcomers to settle territory boundaries and achieve base-line foraging effort. In spring, original owners become subordinate almost immediately after removal. Reductions in settlement cost for newcomers, and increases in territory value, are proposed to accelerate dominance reversal. Age and sex effects on dominance suggest that the value asymmetry rule is modified by variations in resource-holding potential.
Collapse
Affiliation(s)
- J Tobias
- Department of Zoology, University of Cambridge
| |
Collapse
|
45
|
Abstract
The optimum management of women with advanced loco-regional breast cancer (T3-4, N1-2) is controversial. Neoadjuvant therapy in the form of chemotherapy and or radiotherapy is popular and results in an encouraging local response in over 70% of patients. However, should subsequent surgery (either mastectomy or breast conservation treatment) be undertaken in women who respond? We present a prospective evaluation of 15 patients with T3-4, N1-2 tumours (including 1 bilateral cancer) who underwent mastectomy after achieving a complete clinical response to neoadjuvant treatment. All patients had 6 cycles of chemotherapy and 10 also received 50 Gy radiotherapy. In addition to clinical examination, the response to neoadjuvant treatment was assessed by mammography (in all cases) and by magnetic resonance imaging (MR) (in eight patients). Careful histopathological assessment of the breast was undertaken to determine the extent of residual disease. In all patients histological malignancy was recognized within the breast. The size varied from 0.6 to 6.5 cm in maximum diameter with three grade I, eight grade II and five grade III tumours. Axillary lymph nodes were positive in seven patients. In conclusion, surgery is indicated for control of residual disease in locally advanced breast cancer regardless of the response to neoadjuvant treatment. Our preliminary observations suggest a potential role for breast MR in defining the extent of residual disease which may aid in the planning of surgery.
Collapse
Affiliation(s)
- H Mumtaz
- Department of Surgery, University College London Medical School, UK
| | | | | | | | | | | | | |
Collapse
|
46
|
Oliver RT, Tobias J, Gallagher C. Prebiopsy neo-adjuvant endocrine therapy for breast cancer to prevent post-surgery trauma-induced growth factor and immune-suppression mediated tumour progression. Eur J Cancer 1996; 32A:396-7. [PMID: 8814680 DOI: 10.1016/0959-8049(95)00589-7] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Affiliation(s)
- R T Oliver
- Department of Medical Oncology, London Hospital Medical College, UK
| | | | | |
Collapse
|
47
|
Tobias J. In defence of merit awards. West J Med 1994. [DOI: 10.1136/bmj.308.6934.974] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
48
|
Dubinett SM, Patrone L, Huang M, Markowitz J, McBride WH, Economou JS, Tobias J, Kelley D, Yan D, Seelig M. Interleukin-2-responsive wound-infiltrating lymphocytes in surgical adjuvant cancer immunotherapy. Immunol Invest 1993; 22:13-23. [PMID: 8440522 DOI: 10.3109/08820139309066190] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
Wound-infiltrating lymphocytes (WIL) were assessed in murine models of localized sarcoma and carcinoma to evaluate the role of interleukin-2 (IL-2)-responsive lymphocytes in adjuvant immunotherapy. Following tumor resection, IL-2 or diluent was injected at the surgical site for 6 days. Surgical site tissues were harvested and digested in a triple enzyme mixture, and single cell suspensions were prepared. Thy 1.2+ lymphocytes were isolated by incubating cells with monoclonal anti-Thy 1.2 antibody-coated magnetic beads. Lymphocyte-bead complexes were extracted with a magnet and cultured in medium containing IL-2 (100 units/ml) for 1-3 weeks. Perioperative IL-2 immunotherapy led to a three- to four-fold increase in WIL yield. WIL from IL-2-treated mice also demonstrated enhanced cytolysis of the autologous tumor and bound to activated endothelial cells with greater avidity than did the controls. We conclude that perioperative IL-2 therapy augments the yield, as well as the cytolytic and adhesive properties, of wound-infiltrating lymphocytes.
Collapse
Affiliation(s)
- S M Dubinett
- Medical Research Service, Wadsworth Veterans Administration Medical Center, Los Angeles, California
| | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Dubinett SM, Patrone L, Tobias J, Cochran AJ, Wen DR, McBride WH. Intratumoral interleukin-2 immunotherapy: activation of tumor-infiltrating and splenic lymphocytes in vivo. Cancer Immunol Immunother 1993; 36:156-62. [PMID: 8382559 PMCID: PMC11038993 DOI: 10.1007/bf01741086] [Citation(s) in RCA: 24] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/1992] [Accepted: 09/22/1992] [Indexed: 01/30/2023]
Abstract
Direct intratumoral injection of interleukin-2 (IL-2) was evaluated in a murine model. Balb/c mice received 5 x 10(4) Line 1 alveolar carcinoma cells (L1C2) by subcutaneous injection. On the third day following tumor implantation, mice received injections of IL-2 (5 x 10(3)-5 x 10(4) units) or diluent twice daily, either by i.p. or intratumoral injection, 5 days/week for 3 weeks. Intratumoral injection of 5 x 10(4) units IL-2 significantly reduced tumor volume (P < 0.05 versus control), increased median survival time (P = 0.0001), and resulted in a 23.5% cure rate (P = 0.008). There were no long-term survivors in the other treatment groups. Both tumor-infiltrating lymphocytes (TIL) and splenic lymphocytes isolated directly from IL-2-treated mice demonstrated enhanced cytolytic activity compared to diluent-treated controls. To determine whether non-T-cell-mediated antitumor responses were active in our model, intratumoral immunotherapy was evaluated in athymic Balb/c nu/nu mice. In order to decrease the recruitment of lymphocyte precursors, nude mice were splenectomized and received cyclophosphamide prior to tumor injection and IL-2 therapy. Intratumoral IL-2 immunotherapy also significantly decreased tumor volume in these immunodeficient mice (P < 0.02), but did not lead to long-term survival. We conclude that both TIL and splenic lymphocytes are activated in vivo in response to intratumoral IL-2 immunotherapy, suggesting that intratumoral therapy with IL-2 activates both local and systemic antitumor responses.
Collapse
Affiliation(s)
- S M Dubinett
- Pulmonary Immunology Laboratory, UCLA School of Medicine 90073
| | | | | | | | | | | |
Collapse
|
50
|
Sett P, Tobias J, Crockard HA. Eosinophilic Granuloma of Atlanto-Occipital Joint. Skull Base 1992; 2:80-2. [PMID: 17170845 PMCID: PMC1656347 DOI: 10.1055/s-2008-1057114] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
An isolated eosinophilic granuloma at the craniocervical junction was treated by an extreme lateral surgical excision, bone grating, and radiotherapy with good outcome.
Collapse
|